US20050267596A1 - Devices and systems for gastric volume control - Google Patents
Devices and systems for gastric volume control Download PDFInfo
- Publication number
- US20050267596A1 US20050267596A1 US11/121,704 US12170405A US2005267596A1 US 20050267596 A1 US20050267596 A1 US 20050267596A1 US 12170405 A US12170405 A US 12170405A US 2005267596 A1 US2005267596 A1 US 2005267596A1
- Authority
- US
- United States
- Prior art keywords
- balloon
- inflatable
- gastric balloon
- compartments
- space
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
- A61F5/0013—Implantable devices or invasive measures
- A61F5/003—Implantable devices or invasive measures inflatable
- A61F5/0033—Implantable devices or invasive measures inflatable with more than one chamber
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
- A61F5/0013—Implantable devices or invasive measures
- A61F5/003—Implantable devices or invasive measures inflatable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
- A61F5/0013—Implantable devices or invasive measures
- A61F5/0036—Intragastrical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/15—Detection of leaks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1042—Alimentary tract
- A61M2210/1053—Stomach
Landscapes
- Health & Medical Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Nursing (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
A gastric balloon includes a scaffold structure, one or more internal inflatable compartments within the scaffold structure, and one or more inflatable bladders formed over the space-filling compartment. The gastric balloon may be deployed transesophageally using a gastroscope and is inflated in situ, preferably using a combination of liquid and gas inflation media.
Description
- The present application claims the benefit under 35 USC § 119(e) of prior provisional application No. 60/629,800 (Attorney Docket No. 02209-000210US), filed on Nov. 19, 2004; and of prior provisional application No. 60/567,873 (Attorney Docket No. 022209-000200US), filed on May 3, 2004, the full disclosures of which are incorporated herein by reference.
- 1. Field of the Invention
- The present invention relates generally to medical apparatus and methods. More particularly, the present invention relates to the construction and use of gastric balloons for treating obesity.
- Obesity is a serious medical condition and has become a widespread problem in the United States and many other industrialized countries. While many obese patients may be treated by modifications to diet and exercise, a number of morbidly obese patients are resistant to treatment and are candidates for surgical intervention. One surgical approach for treating morbid obesity is referred to as gastric or jejunoileal bypass where a major portion of the gastro-intestinal tract is surgically bypassed. While effective in some patients, gastric bypass procedures can have significant undesirable side affects. Moreover, the initial surgical procedure presents risks associated with open surgery. There are restrictive surgical procedures but they are less effective and still invasive. Consequently, an effective, non-invasive medical treatment with lower risks and minimal side effects is needed for many morbidly obese patients, who cannot tolerate surgical intervention, and most premorbidly obese patients, who have no effective treatment because their condition is not sufficiently severe to qualify them as surgical candidates.
- As an alternative to such surgical procedures, the introduction of space-occupying structures into the stomach, often referred to as “gastric balloons,” has been proposed. Such gastric balloons may be introduced through the esophagus and inflated in situ in order to occupy a significant volume within the stomach.
- Although found to be effective in some cases, the use of gastric balloons has been compromised by a number of deficiencies. The most serious is a sudden or slow deflation of the gastric balloon that can allow the balloon to pass the pyloric valve and enter the intestines. Such unintentional passage of the deflated balloon into the intestines can cause intestinal obstruction and be life-threatening. Consequently, gastric balloons currently marketed outside the US are generally indicated for use of only up to six months.
- The risk of deflation is exacerbated by the fact that the patient may not immediately be aware that the balloon has deflated, delaying the patient from seeing a physician. Thus, it would be desirable to provide approaches to allow a patient to detect leakage or impending leakage. Currently to detect leakage, some practitioners add methylene blue dye to the filling fluid, usually saline, prior to inflation. If the methylene blue leaks into the stomach, a blue color will be present in the patient's excrement. This procedure has a number of deficiencies as evidenced by the continued reports of significant rates of intestinal obstruction and excretion of deflated balloons in clinical practice. Slow and intermittent leaks can release such small amounts of dye that the dye is not detectable in the excrement. Faults on the medical professionals' part include mixing concentrations that makes detection unreliable or simply forgetting to mix in the substance prior to inflating the balloon. On the patients' side, many have difficulties detecting slight changes in the color of the excrement, forget to check diligently, or simply find the task psychologically too unpleasant to perform.
- Other problems include infections resulting from bacterial colonization of the gastric balloon and lack of adequate sizing of the balloon prior to deployment in a patient's stomach. Additionally, most gastric balloons have been filled with saline or other liquid, making them heavy and uncomfortable within a patient's stomach. The weight of the balloons can cause them to induce gastric hypertrophy and create gastric erosions, ulcers, lesions and abrasions within the stomach at the points where they naturally rest.
- For these reasons, it would be desirable to provide improved gastric balloon structures and methods for their use in treating obese patients. The balloons should be durable and the methods and apparatus will preferably be comfortable to the patient and in particular should avoid settling as a heavy weight in the patient's stomach. The gastric balloons and methods for their use should further prevent passage of an accidentally deflated balloon across the pyloric valve and into the intestines, even when the balloon structure is compromised and the balloon looses inflation medium. It would be further desirable if a deflation or impending deflation of the balloon were detectable to the patient in a rapid and reliable fashion. Such a detection system should alert the patient of failure and allow the patient to seek medical help before the balloon has deflated to a size that could pass the pylorus. The compromised device could be then removed or replaced on a timely basis. Additionally, it would be beneficial if the balloons were resistant to bacterial and other microbial growth, thus lessening the risk of infection upon long-term deployment. Other improvements would include balloons and methods for their deployment which allow for proper sizing the balloon and/or trimming or adjusting the balloon size even after deployment. At least some of these objectives will be met by the inventions described below.
- 2. Description of the Background Art
- Gastric balloons and methods for their use in treating obesity are described in U.S. Pat. Nos. 6,746,460; 6,736,793; 6,733,512; 6,656,194; 6,579,301; 6,454,785; 5,993,473; 5,259,399; 5,234,454; 5,084,061; 4,908,011; 4,899,747; 4,739,758; 4,723,893; 4,694,827; 4,648,383; 4,607,618; 4,501,264; 4,485,805; 4,416,267; 4,246,893; 4,133,315; 3,055,371; and 3,046,988 and in the following publications: U.S. 2004/0186503; U.S. 2004/0186502; U.S. 2004/0106899; U.S. 2004/0059289; U.S. 2003/0171768; U.S. 2002/0055757; WO 03/095015; WO88/00027; WO87/00034; WO83/02888; EP 0103481; EP0246999; GB2090747; and GB2139902.
- The present invention provides improved gastric balloons and methods for their deployment and use. The balloons will typically have an overall volume or displacement selected to leave a residual volume in the proximal area of the stomach in the range from 10 ml to 100 ml, usually from 20 ml to 40 ml. As discussed in detail below in some embodiments, the volume will be adjustable to optimize treatment on individual patients. The gastric balloons will typically be designed to conform to the natural shape of the gastric cavity while maintaining the normal function of the stomach. The balloon will preferably have a crescent or “kidney” shape to align the balloon wall against the greater and lesser curvatures of the stomach, an oval cross section to conform to the shape of the cavity in the sagittal plane, and delineate a space proximally for the collection of ingested food and another space distally for active digestion.
- The gastric balloons include at least two principal structural components. The first principal structural component is an expandable scaffold which helps define a shape conforming to a gastric cavity, typically a crescent or “kidney” shape, when expanded. The scaffold may be self-expanding, e.g. formed from a shape memory metal or shape memory polymer, or may be inflatable with an incompressible fluid, such as saline, water, oil, gel, or other liquid, gel, slurry, solution, or the like. Use of an incompressible inflation or filling fluid helps rigidify the scaffold so that it maintains its shape for extended periods when implanted in the stomach. The expanded shape and side of the scaffold by itself or together with an intact portion of the device form an object that is too large in all orientations, even when compressed in peristalsis, to permit the device to pass the pylorus.
- The second principal structural component comprises one or more inflatable or otherwise expandable space-occupying structures or compartments which are secured to the interior and/or exterior of the expandable scaffold. The space-filling structures or compartments assume a space-filling configuration when inflated or otherwise filled or expanded, typically being inflated or filled at least partly with a compressible fluid, typically a gas such as air. Such filling or inflation of the scaffold and/or the space-filling compartment(s) will usually be accomplished from an external pressurized fluid source, but certain gaseous inflation media can be generated in situ within the component by chemical reactions induced by mixing reactants or otherwise initiating a gas-producing chemical reaction. In some cases, the scaffold may form all or a portion of the space-filling structure or compartment.
- The scaffold and the inflatable compartment(s) may be joined together in a number of different ways. Self-expanding scaffolds may be disposed inside of, within, or over the walls of the inflatable compartment(s). The scaffolds may have a number of different geometries, including spines, hoops, serpentine elements, plates, shells, or the like. In one particular embodiment, a self-expanding scaffold comprises a single spine which runs axially along one side of the inflatable compartment(s) with a number of generally oval rib structures extending circumferentially around the inflatable compartment(s). In another specific example, the self-expanding scaffold may be in the form of a plurality of interleaved panels which form an umbrella-like cap on one end of the scaffold, typically the end disposed adjacent to the esophagus after deployment. In still another example, the expandable scaffold may be an inflatable saddle or shell which is attached over an outer surface of one or more inflatable compartment(s). In still other embodiments, the scaffold structure may be formed internally with two or more inflatable compartments disposed on the outside of the structure. For example, in a particular embodiment, the scaffold is inflatable and forms an X-shaped cross section with four inflatable compartments, one in each quadrant of the X. Numerous other particular configurations may be made within the principles of the present invention.
- The gastric balloons of the present invention may comprise two or more walls or layers or lamina of materials to improve the durability of the device by optimizing the performance characteristics of different materials. This is desirable because the maximal thickness of the entire device in its deflated state such that it can be passed uneventfully through the esophagus is limited and is useful even for a simple, single compartment balloon. Typically, the outermost layer is made of materials, such as silicone rubber, selected primarily for their biocompatibility in the stomach and resistance to an acidic environment and the innermost layer is made of materials selected primarily for their resistance to structural fatigue and permeability to the filling fluid. In addition, use of multiple layers allows the layers to be formed from different materials having different properties, to enhance the performance characteristics of the entire balloon structure. The inner layers could have biocompatibility of a shorter duration than the outermost layer. It may be desirable to enhance the durability further by embedding other structural elements in the layers, such as a mesh made of metal, polymer, or high strength fibers, such as Kevlar®. In the simplest embodiment, the two layers are either bonded together to function as a single wall or left unbonded such that the layers could slide by each other except at certain attachment points.
- Optionally, a variety of structural elements may reside in between the outermost and innermost layers. For support, the mesh of high strength fibers, polymer, or metal could constitute another layer in of itself instead of being embedded in the layers. Alternatively, the mesh forms or is a component of the expandable scaffold. One or more layers of materials selected for the optimal balance of biocompatibility, impermeability, rigidity, durability among other criteria could be added to enhance the structural performance characteristics of the device further.
- Optionally, a failure detection system may reside in between any of the layers. This is desirable and useful even for a single compartment balloon. An example of a chemical system is based on a thin film or coating of a substance, such as a dye, that is released into the stomach in the event the integrity of the layer external to the substance is compromised and detected upon excretion or regurgitation by the patient. Optionally, different substances may be placed in between different layers so that the particular layer which failed may be identified based on what is detected. Optionally, the substance could be embedded in the layer so that partial breach of the layer would result in the substance be in contact with the stomach contents. Incorporating the substance(s) in the device eliminates a step for the medical professional to measure and mix the substance(s) into the inflation media. Many errors including mixing ineffective concentrations such that detection becomes unreliable, contaminating the different components such that identification of the particular failed component becomes unreliable, confusing the substance(s) with its respective component, or simply forgetting to mix in the substance(s) are prevented. Furthermore, the detection mechanism is standardized for the device and easier for medical professionals other than the person deploying the device to diagnose any failure.
- The inflatable compartment(s) may be inflated with compressible fluids (gases), incompressible fluids (liquids), or in some cases mixtures of gases and liquids. When multiple inflatable compartments are used, each compartment may be inflated with the same or different gas(es), liquid(s), and/or mixtures thereof. The use of gas and liquid for gastric balloon inflation has a number of advantages. A principal benefit is the ability to control buoyancy and weight distribution within the balloon, e.g., by filling most of the compartments with a gas and distributing the non-gas inflation medium in other compartments throughout the balloon, the risk of concentrated pressure points against the stomach is reduced. Second, by properly controlling the ratio of air or other gas to saline or other liquid, the gastric balloon can be provided with a desired buoyancy and mass within the stomach. Typically, the ratio of air: liquid can be in the range from 2:1 to 10:1, more preferably within the range from 3:1 to 6:1. Such ratios can provide effective densities relative to water at a specific gravity in the range from 0.09 to 0.5, usually from 0.17 to 0.33, depending on the total volume occupied by the device. Typically, the weight of the filled balloon is in the range from 50 gm to 500 gm, usually being from 50 gm to 450 gm. The use of gastric balloons which are light and less dense will reduce the risk that the balloons will cause abrasion, pressure induced lesions, shearing lesions, or other trauma when implanted in the stomach for extended periods of time.
- Optionally, the gastric balloons of the present invention may further comprise at least one separately inflatable or otherwise expandable external bladder formed over an exterior surface of the balloon. The external bladder(s) will be separately inflatable from both the scaffold and the space-filling compartment(s) although they may be attached to or share common walls with either or both of these other principal structural components. The bladder will be positioned on the exterior of the balloon so that it can control either or both of the shape and buoyancy of the balloon as a whole. Typically, the bladder will be inflated at least partly with a compressible gas, typically air or other biocompatible gas. Often, the balloon will be underfilled, i.e., filled with a volume that does not distend or increase the wall tension beyond that of the unfilled bladder.
- The expandable scaffold, the inflatable space-filling compartment(s) or structures, and optionally the inflatable bladder(s) may be joined together in the overall gastric balloon structure in a variety of ways. Typically, each component may be separately formed and joined by adhesives, bonding, or by other non-penetrating fasteners, or by other means. Alternatively, all or a portion of these principal structural components may be formed by co-extrusion to provide the desired inflatable volumes. Generally, however, it will be desirable to avoid penetrating fasteners and/or stitching of the principal structural components since such penetrations can compromise the integrity of the components and subject the balloon to leakage over time.
- The expandable scaffold upon self-compression or inflation may define one or more internal regions or volumes which receive the inflatable compartment(s). In a first exemplary illustrated embodiment, the scaffold when inflated has a X-shaped cross-section which defines four axially aligned quadrants or channels which would allow relatively free passage of food past the scaffold and through the stomach in the absence of the inflated internal component(s). The inflatable scaffold will usually be formed from a non-distensible material so that it can be fully and generally rigidly inflated by the liquid or other incompressible fluid. The internal components, in contrast, may be formed from an elastic and/or inelastic material to permit its volume to be differentially inflated and adjusted. Usually, the space-filling compartment(s) will leave at least a portion of the channels available for the passage of food, albeit in a restricted or modulated fashion. Alternatively, the shape and structure of the entire device could allow ingested food to pass between the exterior and the stomach wall.
- Alternatively, the scaffold could comprise a metal or polymeric scaffold or other open structure which supports the other balloon components but which is not itself inflatable. For example, an open lattice formed from a shape memory material, such as a nickel-titanium alloy, can be compressed and constrained together with the inflatable components for delivering to the stomach. The structure can be self-expanding, i.e. deployed by being released from constraint after delivery to the stomach so that the lattice opens to its memory shape. Such self-expanding scaffolds are preferably collapsible under restraint to a relatively low-profile configuration, typically having a width no greater than about 30 mm, preferably no greater than about 20 mm, in order to permit delivery through a gastroscope or other tubular introducer positioned through the esophagus. For example, the lattice could comprise or consist of one or more axial members having hoop, loop, or rib elements attached along their length(s). Alternatively, the lattice could comprise a plurality of interleaved panels which could be folded and/or rolled into a low width configuration. Other examples include collapsible meshes, collapsible coils, malecot structures, and the like. In contrast, the inflatable components will be deflated to permit introduction in a low profile configuration. The inflatable components can have a variety of geometries including X-shaped cores, inflatable saddles, inflatable caps, and the like. The inflatable components can be deployed by inflation as described elsewhere herein. Alternatively, in some instances, the scaffold might be an outer shell or “exo-skeleton,” in some cases simply being a non-distensible sheath or cover which permits inflation of two or more inflatable compartments therein. Still further alternatively, the scaffold may be formed of a solid material for the attachment of the other components of the device in a particular configuration such that collectively, the components assume the desired physical shape or perform the desired functions.
- The external bladder(s) may also be formed from elastic and/or inelastic materials, such as silicone rubber and polyethylene terephthalate film (Mylar®), respectively, so that they can be inflated at the end of the procedure to properly position the gastric balloon within the stomach and to provide for proper sizing of the balloon within the stomach. In an illustrated embodiment, the gastric balloon includes one space-filling compartment and one external bladder for each of the four channels formed by the inflatable scaffold, but the number of compartments and/or bladders may differ from the number of channels.
- Most embodiments of the present invention will include at least two or more inflatable-space-filling compartments and in some cases may also include one or more inflatable external bladders. The inflation of multiple inflatable compartments and external bladders may be accomplished in a variety of ways. Most simply, each inflatable compartment and inflatable external bladder (if any) could be connected to an independent inflation tube which can be disconnected after inflation. The use of multiple independent inflation tubes allows each inflatable compartment and external bladder to be selectively and independently filled, further allowing filling at different pressures, with different inflation fluids, and the like. The use of multiple inflation tubes, however, is not generally preferred since the tubes, collectively, can have rather a large cross section, and such multiple tubes may interfere with device deployment.
- The multiple inflatable compartments and external bladders of the present invention may be filled through a single inflation tube in at least two ways. First, by connecting the inflatable compartments and external bladders in series, for example using a series of one-way valves, inflation through a first inflatable compartment (or external bladder) can sequentially fill additional compartments and bladders in the series as the pressure in each compartment raises and in turn begins to fill the next compartment or bladder in series. Such an approach, however, is generally less preferred since it does not permit selective filling of the compartments and therefore does not permit the pressure and/or composition of the inflation fluid to be controlled and differentiated between the multiple compartments.
- Thus, a presently preferred structure and method for filling the multiple compartments and external bladders (if any) of the present invention is to use a selective valve system which can be accessed and controlled by a single inflation tube in order to independently and selectively inflate each of the inflatable compartments and external bladders (if any). Such selective valving system may be constructed in any of at least several ways. For example, an inflation tube having a lateral inflation port near its distal end can be disposed between two, three, or more one-way valves opening into respective inflatable compartments and external bladders. By rotating the inflation tube, the inflation port on the tube can be aligned with one of the one-way valves at a time, thus permitting inflation of the respective compartment or bladder to a desired pressure and with a desired inflation fluid, including liquid inflation fluids, gaseous inflation fluids, and mixtures thereof. The rotatable and selectable inflation tube could be removable. Alternatively, at least a portion of the inflation tube could be permanently mounted within the gastric balloon structure, allowing an external portion of the inflation tube to be removably coupled to the internal portion to deliver the inflation fluids.
- In addition to rotatably selectable inflation tubes, the inflation tube could be axially positionable to access linearly spaced-apart one-way valve structures, each of which is connected to a different inflatable compartment or external bladder.
- As a still further alternative, a single inflation tube could be rotatably mounted and have several inflation ports along its lengths. Each of the inflation ports could be disposed near one, two, or more different one-way valves communicating with different inflatable compartments and/or external bladders.
- In all these cases, the one-way valves will permit inflation by introducing an inflation medium at a pressure sufficiently high to open the one-way valve and permit flow into the associated inflatable compartment or external bladder. Upon removing the pressurized inflation source, the one-way valve will close and remain sealed in response to the increased pressure within the inflatable compartment or external bladder.
- In all cases, the inflation tube(s) will be removable from the connected component after the component or multiple components have been inflated. Thus, as described in more detail below, the gastric balloon may be delivered to the stomach in a deflated, low profile configuration, typically through a gastroscope or other transesophageal delivery device. Once in place, the expandable scaffold may be deployed and the inflatable components may be inflated, filled, or otherwise expanded in situ to a desired volume and buoyancy typically by delivering the inflation media through the inflation tubes.
- Once the desired inflation size is reached, the inflation tubes may be detached from each of the compartments allowing self-sealing so that the inflation medium remains contained for extended periods of time. To ensure the containment of the medium, valves may be placed in series for any one or more of the inflatable component(s) and/or bladder(s). Other expansion protocols are described elsewhere herein. In particular, component, compartment, or portion of the balloon may be inflated in situ by inducing a gas-generating reduction within the balloon. The reactant(s) may be present in the balloon prior to introduction to the patient or may be introduced using the connecting tubes after introduction to the stomach.
- Although one illustrated embodiment of the present invention includes four channels in the inflatable scaffold, it will be appreciated that the present invention will cover gastric balloon structures having only a single passage or channel formed within the scaffold with a single space-filling compartment and single external bladder. Embodiments with two channels, space-filling compartments and external bladders as well as three channels, three space-filling compartments, and three external bladders, as well as even higher numbers will also be within the scope of the present invention.
- The dimensions of the scaffold, space-filling compartment(s) or structure(s), external bladder(s), and/or isolated inflation chambers within any or all of these components, will be selected such that the collective volume or physical dimensions of the chambers remaining inflated after deflation of any single chamber (or limited number of chambers) is sufficient to prevent passage of the balloon through the pyloric valve. Usually, the volume(s) will be such that at least two inflatable components and/or chambers within said components could deflate without risk of the “diminished” balloon passing through the pyloric valve, preferably at least three could deflate, and often at least four or more chambers could deflate. The precise volume(s) necessary to prevent passage of the partially deflated balloon structure through the pyloric valve and may vary from individual to individual. A preferred remaining residual inflated volume will be at least about 75 ml, preferably at least about 100 ml and still more preferably at least about 200 ml. After partial deflation, the balloon should have a dimension along any axis or its cross axis of at least 2 cm, preferably at least 4 cm, and most preferably at least 5 cm.
- Should any of the principal structural components or any portion(s) thereof fail, then the present invention optionally provides for failure detection. This is desirable and useful even for a single compartment balloon. For example, a substance may be disposed within any or all (at least one) of the internal volumes of the inflatable scaffold, the inflatable space-occupying component(s), and/or the external bladder (or any chambers therein), where the substance is detectable upon release and excretion or regurgitation by the patient. For example, the substance may be a dye, a scented composition, a benign symptom-inducing agent such as polyvinyl pyrolidine (PVP), or the like. The substance will usually be disposed within each of the inflatable volumes of the scaffold, space-occupying compartment, and the external bladder so that failure of any single component or chamber thereof will be provided. Optionally, different substances may be placed in different components so that the particular component which failed may be identified based on what is detected. The substance may be detectable directly by sight, smell, or sensation, and/or by reaction with water in the toilet optionally with the addition of a detection reagent.
- A particular failure detection system according to the present invention for gastric balloons comprises a chemical and a chemical vapor detector. Optionally, the system includes at least one other chemical or biochemical that reacts with the chemical, its metabolite, or its reaction product. While this invention is described being used in conjunction with a gastric balloon, it does not exclude use in other biomedical devices where signaling a potential failure or malfunction, especially those potentially leading to a catastrophic loss, is desired. The chemical is disposed in a structural component or in an enclosed volume of the device but released into the body upon a breach in the integrity of the device. After release, the chemical, either in its stable form, metabolite, or reaction product is eventually secreted or excreted into the bodily fluids or exhaled gases. The chemical, its metabolite, or reaction product is sufficiently volatile in its secreted or excreted form so that the vapor concentration is significant enough to be detected by a sensor. Optionally, the system could be improved by subjecting the chemical, its metabolite, or reaction product to certain physical perturbation, such as heat or sonic waves, such that the vapor concentration is altered. Alternatively, the system could be improved through a reaction where the chemical, its metabolite, or reaction product is mixed with other chemicals or biochemicals, including solvents, resulting in a product whose vapor concentration has changed enough to be detected by a sensor. Once the sensor is triggered, a signal indicating the compromised state of the device is sent in order to seek medical assistance on a timely basis. The system requires minimal motivation and judgment in diagnosis and enables detecting device failure in a more consistent and reliable fashion at home. The task of checking one's excrement is thereby avoided.
- The chemical could be naturally occurring, synthetic, or made by the human body. Preferably, it is biocompatible to the human body at the concentration that would result if the amount disposed in the device is released completely in one event. Upon such an event, for example, a tear or break in a component, the chemical is released into direct contact with the contents of the body cavity, surrounding tissues or their secretions. It is then absorbed and secreted or excreted in the body fluids or exhaled gases in its stable form. Alternatively, the chemical is metabolized by the body and its metabolites are secreted or excreted in the body fluids. Alternatively, the chemical or its metabolites react with the contents of the body cavity, surrounding tissues or their secretions, or any part of the body until the reactant products are secreted or excreted. The change in vapor concentration of the chemical, its metabolites, and/or reactant products is then detected by the sensor.
- Alternatively, more than one chemical could be disposed separately or together as a mixture in the device. After release, the chemicals are then absorbed and secreted or excreted in the body fluids or exhaled gases in their stable forms. Alternatively, at least one of the chemicals is metabolized by the body and its metabolites are secreted or excreted in the body fluids or exhaled gases and the others could have a separate functions, such as a stabilizing agent or catalyst. Alternatively, at least one of the chemicals reacts with the contents of the body cavity, surrounding tissues or their secretions or any part of the body until the ultimate reactant products are secreted or excreted. Alternatively, at least one of the chemicals or its metabolites or reactant products react with each other in the presence of the contents of the body cavity, surrounding tissues or their secretions or any part of the body until the ultimate reactant products are secreted or excreted. At least one of the products of the reaction is then secreted or excreted in its stable form or as metabolites in the body fluids or exhaled gases. Used as a mixture, the change in vapor concentration of one or more of the chemicals, their metabolites, or their reaction products could be more readily detected to increase sensitivity of the detection system or the change in vapor concentration of more than one increases the specificity.
- Optionally, more than one chemical or more than one mixture of chemicals may be disposed in different parts or components in the device so that more than one part or component which has been compromised may be identified based on which chemical was detected.
- Optionally, more than one chemical or more than one mixture of chemicals may be disposed in the same part or component in the device so that the degree of compromise may be determined based on which chemical or a combination of chemicals was detected.
- The chemical or mixture of chemicals can be disposed anywhere in the device or its components but typically in the wall of the balloon or any part that is more likely to be compromised. It can be distributed evenly throughout the structure or in an irregular fashion but preferably widely enough to cover the potential sites of failure. The preferred configuration is a fine lattice or continuous film of the chemical or chemical mixture embedded in the wall or in between layers of the wall covering the entire balloon, thereby conforming to the shape of the balloon. Such a configuration optimizes the performance of the system in detecting failures early. As the site of the breach cannot be predicted, a breach is unlikely to be missed by covering the entire balloon. Compromise of the balloon typically starts with a somewhat linear split or tear in surface of the balloon wall from mechanical fatigue. As the split propagates, it will soon expose more and more lines of the lattice or area of the film to the stomach contents. Consequently, as the size and seriousness of the breach increases, the more the chemical is released and the probability of detection increases. Being embedded in the wall of the balloon further enables detection before a full breach of the entire thickness of the balloon wall.
- Optionally, the performance could be enhanced by subjecting the chemical, its metabolite, or reactant product to certain physical perturbation, such as heat or sonic waves, such that the vapor concentration is altered. For example, the vapor concentration could be increased in a well heated room or by a toilet flush. Alternatively, the system could be enabled through a reaction where the chemical, its metabolite, or reactant product is mixed with other chemicals or biochemicals (which need not be biocompatible) introduced exogenously and the vapor concentration of the exogenous reaction product is detected by the sensor. For example, a supply of the exogenous chemical can be packaged like a solid toilet bowl cleaner and placed in the water tank. The chemical is dispensed consistently and reliably as a reactant into the bowl. The reaction product in the resulting concentration is at a level necessary for detection but could be bioincompatible had the reaction occurred in the body.
- The chemical vapor detector is based on either the natural olfactory sense or the commercially available technology of so-called “electronic nose”, with which certain chemicals can be detected at levels from parts per million to parts per billion. The detector is preferably powered by batteries and portable enough to be worn on a wristband or belt or can be placed conveniently near the toilet. Upon sensing the chemical, its metabolite, or the reaction product, the detector will alert the patient to seek medical assistance or alert medical professionals directly through other devices, such as Bluetooth linked to an autodial telephone. The alarm could be auditory, such as beeping sounds, visual, such as flashing LED's or a LCD display, sensory, such as vibrations, or preferably a combination of any or all of the above. Optionally, the detector could have different auditory, visual, sensory, or different combinations to identify the source of the detected breach, especially with more than one chemical is used. For example, LED's of different colors or different sounds could be used. The alarm could further indicate the seriousness of the breach. For example, when multiple probes detect a breach, the volume of the alarm would increase to a higher level.
- The present invention further provides a wireless failure detection system for gastric balloons and methods for their deployment and use. While this invention is described being used in conjunction with a gastric balloon, it does not exclude use in other biomedical devices where signaling a potential failure or malfunction, especially those potentially leading to a catastrophic loss, is desired. The failure detection system comprises two probes, a wireless transmitter, and a wireless detector. While this invention is described using radio frequency as the signal transmission of choice, it does not exclude other carrier waves, such as light or acoustic, or via physical properties, such as magnetism or temperature. The probes are connected electronically to the wireless transmitter, which can emit a signal recognized by the detector. Upon direct contact with the stomach contents by the probes, the transmitter is enabled to signal the detector to notify the patient that the integrity of the balloon is compromised and, therefore, seek medical assistance. The system requires minimal motivation and judgment in diagnosis and enables detecting device failure in a more consistent and reliable fashion at home. The task of checking one's excrement is thereby avoided. The system can be designed to function in a variety of algorithms to notify the patient in a simple, unequivocal fashion. For example, in a toggle algorithm, the transmitter is either on in the static state or preferably off in order to reduce the need for power. Upon direct contact with the stomach contents, the probe causes the transmitter to turn the signal off or preferably on to be able to send a wireless signal on a continuous basis. The wireless signal or lack thereof is recognized by the detector to notify the patient that the integrity of the balloon is compromised.
- Alternatively, the algorithm could be based on time, amplitude, frequency, or some other parameter. For example, the transmitter may send a wireless signal at a predetermined time interval in its static state. The detector recognizes the length of the interval as normal and the existence of the signal as the system in working order. Upon direct contact with the stomach contents by the probes, the transmitter is enabled to send the same signal at different time intervals or a different signal, which is recognized by the detector to notify the patient that the integrity of the balloon is compromised. The lack of a signal is recognized by the detector to notify the patient of a detection system malfunction and potential compromise of the integrity of the balloon.
- Optionally, more than one probe or more than one type of probe may be placed internally in different parts or components in the device so that the particular part or component which failed may be identified based on which probe was activated. The transmitter would send different signals for the receiver to display the source of the failure.
- The internal probe could be of any shape and is disposed in the interior or preferably in the wall of the balloon. The preferred configuration is a fine lattice or continuous film of the detection material embedded in the wall or in between layers of the wall covering the entire balloon, thereby conforming to the shape of the balloon. Such a configuration optimizes the performance of the system in detecting failures early. As the site of the breach cannot be predicted, the probe would be unlikely to miss detecting the breach by covering the entire balloon. Compromise of the balloon typically starts with a somewhat linear split or tear in surface of the balloon wall from mechanical fatigue. As the split propagates, it will soon expose more and more lines of the lattice or area of the film to the stomach contents. Consequently, as the size and seriousness of the breach increases, the probability of detection increases. Being embedded in the wall of the balloon further enables detection before a full breach of the entire thickness of the balloon wall. There are further advantages. As the size of the balloon that can pass uneventfully through the esophagus is limited, typically no larger than 2 cm in diameter in its deflated cylindrical shape, the volume of detection material per area of balloon wall is reduced. Furthermore, the lattice or film could provide additional structural support to the device.
- The detection material could be any metal, polymer, fiber, or combination thereof, with or without any coating that can generate an electrical charge or enable flow of electric current when in contact with the stomach contents. For example, an electrical charge could be generated from a non-toxic chemical reaction when the lattice exposed underneath a tear comes in contact with the acidic contents. Flow of electric current could be enabled when two ends of an electric circuit are in contact with electrolytes in the stomach. For example, a charged lattice is embedded in the wall and the ground is the external probe on the surface of the balloon or the lattice is ground and the probe is charged. When the lattice is exposed to the electrolytes in the stomach content, the circuit is closed. Alternatively, the lattice and ground could be separate from each other but interlaced in the wall of the device. Preferred materials include non-corrosive, biocompatible metals and elastomers containing electrically conductive particles.
- The transmitter can be a simple wireless signal generator triggered by an electric current or preferably a transponder using the well-established RFID technology, i.e., produces a wireless signal when triggered by an interrogating signal. The electric charge generated or the electric current enabled by the probe in contact with the stomach contents enables the transmitter to emit or causes it to emit a wireless signal. Typically, the transponder is powered by the interrogating radio frequency signal so that no power source of its own is required. Alternatively, the transmitter could be powered by a micro battery or by the electrical power generated by a chemical reaction. For protection from degradation by an acidic and electrolyte solution and become potentially toxic, the transmitter or transponder circuit is encased in a highly resistant material, such as silicon rubber or stainless steel. The transmitter or transponder circuit can be placed on the exterior, embedded in the wall, or preferably in the interior of the balloon for further shielding from chemical degradation and mechanical stress. It can be placed in any orientation, preferably in the plane where the antenna is most sensitive and the transmitter is most effective in sending and receiving signals through body tissue.
- The wireless signal from the transmitter is recognized by a detector external to the body. The detector could be simply a receiver tuned to the transmitter's signal or, preferably, a combination of both a transmitter of a signal to interrogate the transponder and a receiver to distinguish the different signals from the transponder. The detector is preferably powered by batteries and portable enough to be worn on a wristband or belt or can be placed conveniently near a place where the patient spends most of his time. Upon receiving a signal that a breach has occurred, the detector will alert the patient to seek medical assistance or alert medical professionals directly through other devices, such as Bluetooth linked to an autodial telephone. The alarm could be auditory, such as beeping sounds, visual, such as flashing LED's or a LCD display, sensory, such as vibrations, or preferably a combination of any or all of the above.
- Optionally, the detector could have different auditory, visual, sensory, or different combinations to identify the source of the detected breach, especially with more than one probe or more than one type of probe. For example, LED's of different colors or different sounds could be used. The alarm could further indicate the seriousness of the breach. For example, when multiple probes detect a breach, the volume of the alarm would increase to a higher level.
- As a further option, at least a portion of the exterior of the inflatable balloon will be coated or impregnated with an anti-microbial and/or adhesion resistant agent. Preferably, the entire exposed surface of all components of the balloon will be so coated or impregnated to inhibit colonization of the balloon by bacteria or other microbes, and/or reduce possible accumulation of food particles on the device. Suitable anti-microbial agents include polyethylenetetrafluoride (PTFE), and antibiotics.
- The present invention further provides methods for treating obesity in a patient. The methods comprise introducing a gastric balloon structure to the patient's stomach. An inflatable scaffold which forms part of the balloon is then filled with an incompressible fluid to provide a fixed support geometry. At least a portion of a separate space-filling compartment is then filled at least partly with a compressible fluid, typically a gas such as air, nitrogen, or the like, within the remainder (if any) being filled with an incompressible material, such as a liquid, gel, slurry, or the like. In this way, the buoyancy of the balloon may be controlled within the limits described above.
- The methods of the present invention will usually further comprise determining the size of the gastric cavity and selecting a gastric balloon of proper size prior to introducing the balloon to the stomach. Such size determination may comprise visually examining the gastric cavity, typically under direct observation using a gastroscope, but alternatively using fluoroscopy, ultrasound, x-ray or CAT scanning, or any other available imaging method. An estimate of the dimensions of the stomach and the size of the device can be made by direct observation of the interior of the stomach immediately prior to deployment. Alternatively, the dimensions of the feeding stomach, which is generally larger than the resting stomach, and the size of the device will be determined at an earlier session where the patient has consumed or swallowed a biocompatible filling medium, e.g., water, contrast medium, food, etc. A sufficient amount of filling medium will be consumed so that the imaging technique can detect full relaxation of the stomach during feeding and estimate its dimensions and size.
- Introducing may then comprise passing the gastric balloon in a deflated configuration into the stomach through the same gastroscope. Alternatively, the deflated balloon could be introduced into the gastric cavity via an attachment to an orogastric or nasogastric tube. The balloon will be oriented so that the scaffold will open with curved geometry conforming to the curve of the gastric cavity. Typically, the scaffold will be released from constraint to self-expand or will be filled through a removable inflation tube attached to the scaffold, where the inflation tube may be removed after filling. The scaffold will then be sealed or will more typically be self-sealing upon detachment of the filling tube(s) to prevent loss of the inflating liquid medium. Similarly, the space-filling compartment(s) will also typically be filled through one or more inflation tube(s) removably attached to the compartment(s), where the tube(s) are removed after the compartment(s) have been filled with the desired medium, typically a mixture of liquid and gas sources. Further, the external bladder(s) will typically be filled through one or more inflation tube(s) generally as described above for both the scaffold and the space-filling compartment(s).
- After all the principal structural components of the gastric balloon have been inflated or otherwise expanded and the associated inflation tubes released, any other anchors or tethers attached to the balloon may also be released, leaving the balloon free to “float” within the patient's stomach. By properly selecting the ratio of liquid inflation medium to gas inflation medium, as discussed above, the weight, distribution, and the buoyancy of the gastric balloon will be such that the balloon rests within the stomach without exerting undue pressure at any particular point, thus reducing the risk of abrasions or other trauma to the stomach lining. The inflated gastric balloon may be left in place for extended periods of time, typically as long as weeks, months, or even years.
- After the balloon has been inflated and left in place, it may become desirable to adjust the size and/or buoyancy of the balloon for purposes of patient comfort, efficacy, or other reasons. To perform such adjustments, the balloon will be transesophageally accessed, typically using a gastroscope with suitable working tools introduced therethrough. For example, the balloon may be grasped with graspers and inflation tubes may be suitably attached or docked to inflation ports on the balloon structure. Typically, the inflation ports will all be located near the end of the gastric balloon structure which is oriented toward the top of the stomach so that they are readily accessed through the gastroscope. After attachment with the inflation tube, the inflation medium can be introduced and/or extracted, depending on whether the particular structural component is to be enlarged, deflated, or have a buoyancy adjustment. Optionally, an incising instrument could be introduced through the gastroscope to penetrate and deflate any filled compartment to reduce the overall volume of the device and improve accommodation of the device. Typically, these compartments are small to allow minor adjustments without jeopardizing the integrity of the device itself.
- In addition to adjusting the size and/or buoyancy of the gastric balloon, it may become desirable or necessary to remove the balloon completely. To effect such removal, the balloon will again be accessed transesophageally, typically using a gastroscope. The balloon will first be grasped or secured using a grasping tool. Then, one or more surfaces of the balloon may be penetrated or breached in order to release the contents of the balloon into the stomach. The contents will be biocompatible gasses or liquids so that release into the stomach will not be a concern. After the contents of the compartments have been released, the balloon may then be pulled through the patient's esophagus, typically by pulling with the grasping tool. It may be possible to pull the deflated gastric balloon through the working channel of the gastroscope, but more often the balloon will simply be withdrawn through the esophagus as the gastroscope is withdrawn. Optionally, a sheath or other protective cover may be placed over the deflated balloon in order to reduce the risk of trauma or injury to the esophagus upon withdrawal.
-
FIG. 1 is a side view of a gastric balloon constructed in accordance with the principles of the present invention, shown deployed in a stomach. -
FIG. 2 is a cross-sectional view taken along line 2-2 inFIG. 1 . -
FIG. 3 is a top view of the gastric balloon ofFIG. 1 , illustrating the inflation ports or nipples. -
FIGS. 4A and 4B illustrate use of tools introduced through a gastroscope for inflating and deflating the gastric balloon ofFIG. 1 , respectively. -
FIGS. 5A through 5E illustrate a complete deployment protocol according to the methods of the present invention. -
FIG. 6 is a frontal view of a gastric balloon with an optional material incorporated in a lattice configuration in the wall of the device constructed in accordance with the principles of the present invention. -
FIGS. 7A through 7C are enlarged, peeled-back, cross-sectional views of a portion of the multi-layered wall of the gastric balloon ofFIG. 6 constructed in different configurations in accordance with the principles of the present invention. -
FIG. 8 is a magnified cross-sectional view with an element in a thin film configuration and in a lattice configuration in between layers of materials used in construction of the balloon. -
FIG. 9 is a frontal view of the portable detector with an example of a failure display and auditory alarm constructed in accordance with the principles of the present invention. -
FIG. 10 illustrates an alternative balloon geometry in accordance with the principles of the present invention, shown deployed in a stomach. -
FIG. 11 illustrates first embodiment of a self-expanding scaffold for the balloon geometry ofFIG. 10 . -
FIG. 12 illustrates a second embodiment of a self-expanding scaffold geometry for a balloon having the geometry ofFIG. 10 . -
FIG. 13 illustrates an inflatable scaffold suitable for use with a balloon having the geometry ofFIG. 10 . -
FIG. 13A is a cross-sectional view taken alongline 13A-13A ofFIG. 13 . -
FIG. 14 illustrates a gastric balloon in accordance with the principles of the present invention including a pair of inflatable space-filling compartments contained by an external sheath. -
FIG. 15 illustrates a gastric balloon having two inflatable space-filling compartments joined together by a spine structure. -
FIGS. 16-18 are flow diagrams illustrating several valving systems suitable for inflating gastric balloons having multiple inflatable compartments and optionally internal bladders in accordance with the principles of the present invention. -
FIG. 19 illustrates an exemplary structure for valving according toFIG. 16 . -
FIGS. 20, 20A , and 20B illustrate an exemplary structure for valving according toFIG. 18 . - Referring now to
FIGS. 1 and 2 , agastric balloon 10 constructed in accordance with the principles of the present invention comprises aninflatable scaffold structure 12, four inflatable space-fillingcompartments 14, and four inflatableexternal bladders 16. Referring in particular toFIG. 2 , theinflatable scaffold 12 has a X-shaped cross-section and defines four generally axially oriented channels or quadrants, each of which receives one of the four inflatable space-fillingcompartments 14. The four inflatableexternal bladders 16 are mounted over the inflatable space-fillingcompartments 14, and theballoon 10 includes anupper cage 18 andlower cage structure 20 which permit grasping of the balloon using grasping tools, as will be described in more detail below. In its deployed configuration, thegastric balloon 10 has a crescent or curved shape which conforms to the interior shape of a gastric cavity, with theupper cage structure 18 oriented toward the esophagus E, thelower cage structure 20 oriented toward the pyloric valve PV. - Referring now to
FIG. 3 , theinflatable scaffold structure 12 is provided with at least one inflation port or nipple 22 while the inflatable space-fillingcompartments 14 are provided with aseparate port 24 and the inflatable external bladders are provided with aseparate inflation port 26. Although not illustrated, the scaffold, internal components, and external bladders could have isolated, inflatable volumes therein, each of which would be attached to a separate inflation tube. By “subdividing” the volume of the various principal structural components, the risk of accidental deflation of the balloon is further reduced. - As illustrated in 4A, after the
gastric balloon 10 is introduced in its deflated configuration into the gastric cavity, the inflatable structural components could be inflated using asingle inflation tube 30 introduced through the gastroscope G, or orogastrically or nasogastrically by itself or using an orogastric or nasogastric tube. Typically, theupper cage 18 will be held by agrasper 32 which can selectively hold and release thegastric balloon 12 during inflation and subsequent deployment. Shown inFIG. 4A ,inflation tube 30 can be selectively coupled to any one of theinflation ports Inflation tube 30 will be suitable for delivering either liquid or gas inflation media, typically including saline, water, contrast medium, gels, slurries, air, nitrogen, and the like. - Usually, the
inflatable scaffold structure 12 will be inflated entirely with a liquid or other incompressible medium, such as a gel, slurry, or the like. In contrast, the inflatable space-fillingcompartments 14 will at least partly be inflated with air or other gas. Often, however, the inflatable space-filling compartments will inflated with a mixture of gas and liquid in order to control the buoyancy of theballoon 12. Finally, theexternal bladders 16 will typically be inflated with gas in order to provide a relatively soft outer surface which can reduce trauma and abrasion. - The various structural compartments of the balloon may be made from the same or different materials. Usually, the
inflatable scaffold structure 12 will be formed from a non-distensible (non-stretching) material so that it may be inflated to become a relatively rigid structure. Alternatively, or additionally, the structures may be formed from stiffer materials and/or be reinforced to increase the rigidity when inflated. - In contrast, the inflatable space-filling
compartments 14 and theinflatable bladders 16 may be formed in whole or in part from softer elastomeric materials in order to allow inflation flexibility, both in terms of size and density of the combined inflation media. The elastic nature of the external bladders allows the peripheral dimensions of the gastric balloon to be adjusted over a significant range by merely controlling inflation volume. Elastic inflatable space-filling compartments can allow the amount of space occupied in the interior of the balloon to be adjusted, for example to adjust the amount of volume filled by the balloons within the quadrants defined by thescaffold structure 12. Alternatively, the volume of incompressible fluid introduced into non-elastic structures may be sufficient to control the volume being occupied. - As an alternative to using a single inflation tube, each of the
inflation ports gastric balloon 10 in place. - Referring now to
FIG. 4B , theballoon 10 can be deflated while grasping thetip 18 of the balloon withgrasper 32 through gastroscope G using ablade structure 40 introduced through the gastroscope. Theblade structure 40 will preferably be used to make one or more penetrations or breaches within each of the inflatable components of the gastric balloon, including the inflatable scaffold, the inflatable space-filling compartment(s), and the inflatable external bladder(s) - Referring now to
FIGS. 5A-5E ,gastric balloon 10 is introduced to a patient's stomach S using a gastroscope G introduced through the esophagus E in a conventional manner. Standard procedures for preparing and introducing the gastroscope are employed, including checking for ulcerations in the esophagus and performing further examination if warranted. - After introducing the gastroscope G, the size of the gastric cavity within stomach S can be estimated and a balloon of an appropriate size selected. The
balloon 10 is then also introduced through the esophagus E (orogastrically or nasogastrically) using an appropriate catheter or optionally using the inflation tube(s) which will be used to inflate the balloon. After the entire balloon is confirmed to be in the stomach at a proper orientation, typically using the gastroscope G, the various components of theballoon 10 may be inflated as shown inFIGS. 5C and 5D . First, theinflation tube 32 attached to the port which is coupled to thescaffold 12 is inflated, typically using saline or other incompressible liquid until the scaffold structure becomes relatively rigid, as shown inFIG. 5C . During this inflation, theballoon 10 is held by at least aninflation tube 32 and may optionally be held by additional inflation tube(s) and/or agrasper 32. - After the
scaffold 12 has been inflated, an additional syringe is used to inflate the space-filling compartments through asecond inflation tube 33, as shown inFIG. 5D . The space-filling compartments, again, will typically be inflated with a combination of saline or other liquid and air or other gas in order to achieve the desired density of the inflation medium therein. Theexternal bladders 16 will be inflated in a similar manner, typically using air or other gas inflation medium only. - When it is desired to remove the
gastric balloon 10, the balloon may be deflated as previously discussed and removed through the esophagus using agrasper 32 passing through the gastroscope G, as shown inFIG. 5E . Typically, the balloon will be pulled out using both the gastroscope and thegrasper 32. - Referring now to
FIG. 6 , agastric balloon 100 of a single compartment constructed in accordance with the principles of the present invention. As illustrated inFIG. 7A , the wall of the balloon comprises at the minimum anoutermost layer 102 andinnermost layer 104. The layers are manufactured by either dipping a mold successively into solutions of different materials that dry and cure or preferably by successive precision injections of materials into a mold. Typically, theoutermost layer 102 is made of one or more materials, such as silicone rubber, selected primarily for their non-abrasiveness, biocompatibility in the stomach, and resistance to an acidic environment. Typically, theinnermost layer 104 is made of materials selected primarily for their resistance to structural fatigue and impermeability to the filling fluid. Theinner layer 104 could have biocompatibility of a shorter duration than the outermost layer. The two layers are either bonded together to function as a single wall or left unbonded such that the layers could slide by each other except at certain attachment points. - Referring now to
FIG. 7B , it may be desirable to enhance the durability further by incorporating other structural elements in the layers, such as amesh 106 made of metal, polymer, or high strength fibers, such as Kevlar, or the scaffold (not shown). The mesh could constitute a separate layer as illustrated inFIG. 7B or instead, could be embedded in one of the layers of material, as shown embedded inlayer 104 inFIG. 7C . Amesh 106 could inhibit the propagation of a tear in the layers. Many of these materials are radio-opaque which enables imaging clearly the entire shape of the device using plain diagnostic X-ray radiography. - As illustrated in
FIGS. 7B and 7C , in addition to layers of 102 and 106, one or more layers, 108 and 110, of materials selected for the optimal balance of biocompatibility, impermeability, rigidity, shear resistance among other criteria could be added to enhance the structural performance characteristics of the device further. - Referring now to
FIG. 7B , layers, 108 and 110, could also represent other materials incorporated to enable or enhance certain functional performance characteristics of the device. Instead of disposing the detection marker in the enclosed volume of the balloon, the marker may reside in between any of the layers either in a thin film or in a lattice configuration. It is also possible to dispose the marker in the open spaces in the mesh (not shown). A thin film or coating of a substance that is detectable upon excretion or regurgitation by the patient, such as a dye, would be released into the stomach in the event the integrity of the layer external to the substance is compromised. For example, the substance that forms thin film is released into the stomach when a breach, such as a tear, occurs inlayer 102. - Referring now to
FIG. 7C , as an optional configuration, different substances, 108 a and 108 b, may be placed in between different layers so that the particular layer which failed may be identified based on what is detected. For example, if 108 a were detected in the excrement, one would deduce thatlayer 102 has been breached butlayer 110 has not. This would constitute a situation where medical assistance can be provided on an elective basis. Once 108 b is detected in the excrement, one would deduce that at the minimum, layers 108 and 110 have both been compromised leavingonly layer 104 as possibly the last line of defense. This would represent a medical emergency where the device should be removed before complete failure. - Another failure detection system comprises a chemical substance and a chemical vapor detector, an “electronic nose,” that detects a change in vapor concentration of the substance, its metabolite, or any of its reaction products. Optionally, it includes at least one other chemical or biochemical that reacts with the chemical, its metabolite, or any of its reaction products to enhance the sensitivity and/or specificity of detection. When used in conjunction with a biomedical device, the system represents a method to detect early potential failure or malfunction involving a structural breach. While this invention is described being used in conjunction with a gastric balloon, it does not exclude use in other biomedical devices where signaling a potential failure or malfunction, especially those potentially leading to a catastrophic loss, is desired.
- Referring again to
FIG. 6 , thegastric balloon 100 includes a chemical substance in alattice configuration 110 incorporated in the wall of the balloon. The chemical substance could be naturally occurring, synthetic, or made by the human body. As magnified inFIG. 8 , the chemical substance can be disposed in afine lattice configuration 110 and/or in athin film configuration 112 in the wall of the balloon in between two or more layers, e.g.,outermost layer 102 andinnermost layer 104. The chemical substance can be also disposed in any enclosed space in the device (not shown) - After the
balloon 100 is deployed in the stomach, the chemical substance comes in contact with and is released into the surrounding tissue and body fluids upon a breach in the integrity of the wall. As illustrated inFIG. 8 , thechemical substance 112 comes in contact with and is released when there is a tear in theoutermost layer 102 of the balloon wall. After release, the chemical substance, either in its stable form, its metabolite, or reaction product is eventually secreted or excreted into the bodily fluids. The chemical substance, its metabolite, or reaction product is sufficiently volatile in its secreted or excreted form so that the change in vapor concentration of the secreted or excreted form is significant enough to be detected by a chemical vapor sensor. The chemical vapor detector is based on either the natural olfactory sense or the commercially available technology of so-called “electronic nose”, with which certain chemicals can be detected at levels from parts per million to parts per billion. - Referring now to
FIG. 9 , the sensor, power source, and electronic circuit is enclosed withindetector 120. Thedetector 120 is preferably powered by batteries and portable enough to be worn on a wristband or belt or can be placed conveniently near the toilet. Upon sensing the chemical substance, its metabolite, or a reaction product, the detector will alert the patient to seek medical assistance. The alarm could be visual, such as lit or blinking LED's 122 and 124, and can designate different levels of urgency depending on what was detected. For example, a litLED 122 could indicate thatchemical substance 112 inFIG. 8 has been detected. It can be deduced thatlayer 102, external to 112 has been breached. Since there are still more than two layers to breach before complete breach of the balloon wall, medical assistance can be provided on an elective basis. In the same fashion, a litLED 124, could indicatechemical substance 110 has been detected, and therefore layer 106 external to 110 has been breached. Since onlylayer 104 remains as the last barrier to complete breach of the wall and when that occurs cannot be predicted, the device needs to be removed on an emergent basis. Apower light 121 is provided to assure the device is on. - Shown in
FIG. 9 , thealarm 126 could also be auditory, such as beeping sounds, or sensory, such as vibrations, or preferably a combination of any or all of the above. Optionally, the detector could have different auditory, visual, sensory, or different combinations to identify the source of the detected breach, especially with more than one chemical substance used. The alarm could further indicate the seriousness of the breach. For example, when breaches are detected, the volume of the alarm would increase to a higher level. - Optionally, the system could be improved by subjecting the chemical, its metabolite, or reaction product to certain physical perturbation, such as heat or sonic waves or a toilet flush, such that the vapor concentration is altered. Alternatively, the system could be improved through a reaction where the chemical substance, its metabolite, or reaction product is mixed with other chemicals or biochemicals, including solvents, resulting in a product whose vapor concentration has changed enough to be readily detected by a sensor.
- Optionally, detecting the change in vapor concentration of more than one of the chemical substance, its metabolites, or its reaction products could increase the sensitivity and/or specificity of the detection system.
- Another failure detection system comprises two electrical probes, wireless transmitter, and a wireless detector. While this invention is described using radio frequency as the signal transmission of choice, it does not exclude other carrier waves, such as light or sonic, or via physical properties, such as magnetism or temperature. When used in conjunction with a biomedical device, the system represents a method to detect early potential failure or malfunction involving a structural breach. When used in conjunction with a biomedical device, the system represents a method to detect early potential failure or malfunction involving a structural breach. While this invention is described being used in conjunction with a gastric balloon, it does not exclude use in other biomedical devices where signaling a potential failure or malfunction, especially those potentially leading to a catastrophic loss, is desired.
- Referring now to
FIG. 6 , thegastric balloon 100 includes two electric probes.Probe 130 is on the external surface in contact with the surrounding tissues, body fluids, and contents of the stomach. Thelattice configuration 10 provides the second probe incorporated in the wall of the balloon. The probe material could be any metal, polymer, fiber, or combination thereof, with or without any coating that can generate an electrical charge or enable flow of electric current when in contact with the stomach contents. The probes are connected electronically to thewireless transmitter 140, but are separated from each other by at least one layer of non-conductive material in the balloon wall. The transmitter can be a simple wireless signal generator triggered by an electric current or preferably is a transponder using the well-established RFID technology, i.e., produces a wireless signal in response when triggered by an interrogating signal. In the intact state, 130, 110, and 140 represent an open electrical circuit and the transmitter is enabled to transmit a base signal. - As magnified in
FIG. 8 , the internal probe can be in afine lattice configuration 110 or in athin film configuration 112 in the wall of the balloon in between, at the minimum two layers, anoutermost layer 102 andinnermost layer 104. The internal probe can be also disposed in any enclosed space in the device (not shown). In the configuration described inFIG. 8 , probes 130 and 110 andtransponder 140 represent one open circuit and probes 130 and 112 andtransponder 140 represent a second open circuit. Each open circuit enables the transponder to transmit a base signal. - After the balloon is deployed in the stomach, the
external probe 130 is in contact with the surrounding tissue and body fluids and stomach contents. Upon a breach in the integrity of the wall, such as a tear in theoutermost layer 102 as illustrated inFIG. 8 , the leakage of physiologic fluid or stomach contents with electrolytes into the tear forms a salt bridge that closes the circuit formedprobes transponder 140. Once the circuit is closed, a toggle is switched in the transponder, which will be enabled to transmit a “layer 102 breach” signal. Tears throughlayer 106 in the balloon wall will allow leakage of physiologic fluid or stomach contents with electrolytes into the tear forming a salt bridge that closes the circuit formedprobes transmitter 140. Closing this circuit switches another toggle in the transponder, which will be enabled to transmit a “layer 106 breach” signal. -
FIG. 10 illustrates an alternative crescent-shaped balloon geometry suitable for use in the gastric balloons of the present invention.Gastric balloon 200 has a generally flat or truncatedupper surface 202 which is positioned adjacent to the esophagus E. Alower end 204 is also generally flat or truncated. These flat ends 202 and 204 are distinguishable from the more tapered ends of the prior gastric balloon embodiments. Although illustrated schematically as a single unit or structure, it will be appreciated that theballoon 200 will usually comprise multiple independently inflatable space-filling compartments and optionally further comprise external inflatable bladders. The geometry shown inFIG. 10 is intended to illustrate the peripheral shape of the device including all components. - Referring now to
FIGS. 11-15 , gastric balloon structures having the geometry ofballoon 200 inFIG. 10 may be deployed using a number of different expandable scaffolds. For example, as shown inFIG. 11 , theballoon structure 200 may include an external “exo-skeleton” 210 comprising aspine 212 and a plurality ofribs 214 extending laterally from the spine. Thespine 212 andribs 214 are preferably made from elastic components, such as nickel titanium alloys or other super elastic materials, permitting them to be folded and compressed to a small width for introduction. The scaffold will then be deployed by releasing the scaffold from constraint after it has been positioned within the stomach. - The
balloon 200 may also be mated with anend cap 220. Theend cap 220 may include, for example, a plurality of interlaced panels which can be folded down to a low profile configuration for delivery. The panels may be composed of elastic polymers, shape memory metals, shape memory polymers, or the like. The use ofend caps 220 is particularly useful when the balloon will itself comprise a single compartment. The end cap will prevent accidental passage of the balloon through the pylorus even upon rapid deflation of the balloon. - The
balloon 200 may also be mated to aninflatable scaffold 230, which may be conveniently formed into the shape of a saddle, as shown inFIGS. 13 and 13 A. Theballoon 200 may comprise one, two, or more separate inflatable compartments. Each of these compartments, as well as theinflatable scaffold 230, will require separate inflation, preferably using one of the valving mechanisms described hereinbelow. Theinflatable scaffold 230 could have other configurations as well, such as being in the form of a lattice with a central inflatable spine and multiple arms disposed laterally outwardly about the remainder of theballoon 200. - Referring now to
FIGS. 14 and 15 , theballoon 200 may comprise first and second internalinflatable compartments exoskeleton 244. Thesheath 244 may be, for example, a non-distensible outer tubular structure having the desired crescent geometry, with theinflatable compartments inflatable compartments exoskeleton 244 could be made to be non-collapsible in order to prevent accidental passage of the balloon through the pyloric valve in case of unintended deflation of both of theinflatable compartments - The
compartments spine element 250, as shown inFIG. 15 . The balloons would be attached to the spine, optionally by heat sealing or adhesives, usually one ormore fasteners 252, such as adhesive straps, are provided about the periphery of theinflatable compartments spine 250 can also optionally be used to receive and deploy inflation tubes, as described in more detail below. - Each of the
balloons 200 described above will be provided with a valve mechanism or assembly to permit selective inflation with liquid fluids, gaseous fluids, or a combination thereof. If only a single inflatable compartment is utilized, the valving mechanism could be simply a one-way valve having a connector for releasably connecting to an inflation tube. For example, the inflation tube could be connected to the connector on the valve prior to introduction of the balloon in the patient's stomach. After introduction, the inflation medium could be introduced through the tube, and the tube detached and removed after inflation is complete. Optionally, the inflation tube could be introduced later for reinflation of the balloon if desired. - When two or more inflatable compartments, and optionally external bladders, are provided, the valve assemblies of the present invention will preferably provide for selectively delivering inflation medium to individual inflation ports on each of the inflatable compartments, external bladders, and optionally inflatable scaffolds. Inflation valves will usually comprise a one-way valve structure, such as a flap valve or a duckbill valve. The valves associated with each compartment will be arranged to permit manipulation of an associated inflation tube so that the valve is in line with an inflation port on the inflation tube to permit delivery of inflation medium.
- In
FIG. 16 , for example, a first one-way valve 300 can be mounted on a wall of a first balloon compartment and a second one-way valve 302 can be mounted on the wall of a second balloon compartment. By then arranging the two valves in opposite directions along a common axis, aninflation tube 304 having arotatable inflation port 306 can be disposed between the two valves. Then by turning the inflation tube, thefirst valve 300 or thesecond valve 302 may be selected to deliver inflation medium through thesingle inflation tube 304. - Alternatively, as shown in
FIG. 17 , afirst inflation valve 310, asecond inflation valve 312, and athird inflation valve 314, each of which is associated with a respective balloon compartment, may be axially arranged so that asingle inflation tube 316 may be translated to successfully access each of the one-way valves 310. In this way, each of the associated balloon compartments may be selectively inflated and reinflated by simply axially translating theinflation tube 316. - As a further alternative, as shown in
FIG. 18 , asingle inflation tube 320 havingmultiple inflation ports way inflation valves inflation tube 320, the valves can be selected by rotating the tube so that only a single inflation port is aligned with a single one-way valve at one time. - It will be appreciated that the above-described valve mechanisms and assemblies may be constructed in a wide variety of ways using a wide variety of one-way valve structures. For the purposes of the present invention, it is desirable only that the valve structures permit selective introduction of an inflation medium to individual balloon compartments using a single inflation tube. It will also be appreciated that more than one valve may be used in series (not shown) in place of a single valve to reduce further the potential for leakage of the filling media.
- A first specific structure for implementing the inflation assembly of
FIG. 16 is shown inFIG. 19 . Theinflation tube 304 havinginflation port 306 is disposed between awall 350 of a first balloon and awall 352 of a second balloon. The first one-way valve 300 is positioned through thefirst wall 350, and the second one-way valve 302 is positioned through thesecond wall 352. Those valves are shown as duckbill valves. As shown inFIG. 19 , theport 306 is aligned with the first one-way valve 300 so that introduction of a pressurized inflation medium throughlumen 305 of theinflation tube 304 will open the duckbill valve and allow inflation medium to enter the first balloon. By then rotating theinflation tube 350 by 180° so that it is aligned with thesecond valve 302, inflation medium can be similarly delivered to the second balloon. - A specific valve system constructed generally as shown in
FIG. 18 is shown inFIGS. 20, 20A and 20B. Theinflation tube 320 is rotatably disposed within anouter tube 360 which passes betweenwalls way valve 334 is disposed in a first radial direction on theouter tube 360, and the next inner one-way valve 332 is offset by 90°. Theports FIGS. 20A and 20B not illustrated) will be arranged so that in a first rotational position oneport 362 is aligned with one-way valve 332 and in a second rotational position, asecond port 364 is aligned with one-way valve 334. At no time, however, is more than one inflation port aligned with more than one one-way valve on theouter tube 360. Thus, by rotatinginflation tube 320, individual inflatable compartments can be inflated. - While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.
Claims (34)
1. A gastric balloon comprising:
a scaffold having a constrained configuration and a deployed, wherein the scaffold can be introduced into a gastric cavity in the constrained configuration; and
at least one inflatable space-filling compartment secured to the scaffold, said compartment assuming a space-filling configuration when inflated at least partly with a compressible or incompressible fluid.
2. A gastric balloon as in claim 1 , wherein the space-filling compartment(s) have a generally crescent shape when at least partly inflated with the fluid.
3. A gastric balloon as in claim 2 , wherein the scaffold is a resilient structure which conforms to the crescent shape of the space-filling compartment when the scaffold is deployed.
4. A gastric balloon as in claim 2 , wherein the scaffold is an inflatable structure which conforms to the crescent shape of the space-filling compartment when the scaffold is deployed by inflation.
5. A gastric balloon as in claim 2 , wherein the scaffold is inflatable with a compressible or an incompressible fluid.
6. A gastric balloon as in claim 1 , wherein the scaffold forms a plurality of longitudinal channels, and the inflatable space-filling compartment(s) is (are) disposed in at least some of the channels, to occupy at least a portion thereof when inflated.
7. A gastric balloon as in claim 1 , wherein the scaffold has an X-shaped cross-section to define channels in four quadrants and the inflatable space-filling compartment includes at least one section in each of the quadrants.
8. A gastric balloon as in claim 1 , comprising a plurality of separately inflatable space-filling compartments.
9. A gastric balloon as in claim 8 , comprising at least three separately inflatable space-filling compartments.
10. A gastric balloon as in claim 9 , comprising at least four separately inflatable space-filling compartments.
11. A gastric balloon as in claim 1 , further comprising at least one inflation tube removably connected to the space-filling compartment(s).
12. A gastric balloon as in claim 11 , wherein a separate inflation tube is connected to each of the space-filling compartments.
13. A gastric balloon as in claim 11 , wherein a single inflation tube is commonly connected to all of the space-filling compartments.
14. A gastric balloon as in claim 13 , wherein the gastric balloon comprises a plurality of inflatable compartments, further comprising a valve structure which connects the single inflation tube to the plurality of inflatable compartments and which permits a user to selectively inflate each inflatable compartment.
15. A gastric balloon as in claim 1 , further comprising at least one separately inflatable external bladder formed over the space-filling compartment(s), wherein the bladder shapes the outside of the balloon when inflated at least partly with a compressible or incompressible fluid.
16. A gastric balloon as in claim 15 , further comprising at least one inflation tube removably connected to the external bladder.
17. A gastric balloon as in claim 1 , further comprising at least one substance disposed within the wall or interior of at least one of the inflatable space-filling compartment(s), wherein the substance is detectable upon release from the balloon due to breach and secretion, excretion, exhalation, and/or regurgitation by the patient.
18. A gastric balloon as in claim 11 , further comprising a wireless breach detection system, incorporated into a wall of at least one space-filling compartment, wherein said system is adapted to emit a detectable signal if the wall is at least partially breached.
19. A gastric balloon as in claim 1 , wherein at least a portion of the inflatable space-filling compartments are coated with or impregnated by an anti-microbial and/or adhesion-resistant agent.
20. A gastric balloon as in claim 19 , wherein all exposed surfaces of the gastric balloon are coated with the agent(s).
21. An improved gastric balloon of the type having an inflatable chamber, wherein the improvement comprises having a plurality of inflatable compartments, wherein the compartments have individual volumes such that the collective volume of the chambers remaining inflated after the deflation of any single chamber is such that the balloon is prevented from passing through the pyloric valve.
22. An improved gastric balloon as in claim 21 , further comprising a substance disposed within at least some of the inflatable compartments or walls of the inflatable compartments, wherein the substance is detectable upon excretion, secretion, exhalation, or regurgitation by a patient.
23. An improved gastric balloon as in claim 21 , further comprising a wireless breach detection system incorporated into at least one wall of one inflatable compartment.
24. An improved gastric balloon of the type including at least one inflatable space-filling compartment, further comprising a self-expanding scaffold which has a size or geometry which prevents the balloon from passing through the pyloric valve after accidental deflation of the inflatable compartments.
25. An improved gastric balloon as in claim 24 , further comprising a substance disposed within at least some of the inflatable compartments or walls of the inflatable compartments, wherein the substance is detectable upon excretion, secretion, exhalation, or regurgitation by a patient.
26. An improved gastric balloon as in claim 24 , further comprising a wireless breach detection system incorporated into at least one wall of one inflatable compartment.
27. An improved gastric balloon of the type comprising an inflatable compartment having a wall subject to breach, said improvement comprising:
a wall formed from at least two layers, wherein each layer has different physical and/or mechanical properties.
28. An improved balloon as in claim 27 , wherein the properties are selected from the group consisting of stiffness, durability, biocompatibility, chemical resistance, and permeability.
29. An improved balloon as in claim 27 , further comprising a detectable material present between said layers so that the material is released in the event the wall is breached.
30. An improved gastric balloon of the type comprising an inflatable compartment having a wall subject to breach, said improvement comprising:
a detectable material present in the wall such that the material is released if the wall is breached.
31. An improved gastric balloon as in claim 30 , wherein the detectable material is dispersed within the wall.
32. An improved gastric balloon as in claim 30 , wherein the detectable material is disposed between two layers of the wall.
33. An improved gastric balloon of the type comprising an inflatable compartment having a wall subject to breach, said improvement comprising:
a wireless detection system including two probes, wherein the probes are arranged so that the probes are exposed to stomach contents only upon breach of the wall; and
a transmitter which is connected to the probes and powered when the probes are exposed to stomach contents.
34. An improved balloon as in claim 33 , wherein at least one of the probes is a mesh embedded in the wall and the other probe is external to the wall.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/121,704 US20050267596A1 (en) | 2004-05-03 | 2005-05-03 | Devices and systems for gastric volume control |
US11/170,274 US8070807B2 (en) | 2004-11-19 | 2005-06-28 | Wireless breach detection |
JP2007543307A JP4839321B2 (en) | 2004-11-19 | 2005-11-18 | Wireless tear detection |
AU2005306367A AU2005306367B2 (en) | 2004-11-19 | 2005-11-18 | Wireless breach detection |
EP05824820A EP1811920A4 (en) | 2004-11-19 | 2005-11-18 | Wireless breach detection |
PCT/US2005/041960 WO2006055839A2 (en) | 2004-11-19 | 2005-11-18 | Wireless breach detection |
US11/282,224 US20060111632A1 (en) | 2004-11-19 | 2005-11-18 | Wireless breach detection |
US12/504,468 US20090275973A1 (en) | 2004-05-03 | 2009-07-16 | Devices and systems for gastric volume control |
US14/964,119 US20160095730A1 (en) | 2004-05-03 | 2015-12-09 | Devices and systems for gastric volume control |
US14/964,068 US20160081831A1 (en) | 2004-05-03 | 2015-12-09 | Devices and systems for gastric volume control |
US14/971,795 US9445930B2 (en) | 2004-11-19 | 2015-12-16 | Methods, devices, and systems for obesity treatment |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56787304P | 2004-05-03 | 2004-05-03 | |
US62980004P | 2004-11-19 | 2004-11-19 | |
US11/121,704 US20050267596A1 (en) | 2004-05-03 | 2005-05-03 | Devices and systems for gastric volume control |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/504,468 Continuation US20090275973A1 (en) | 2004-05-03 | 2009-07-16 | Devices and systems for gastric volume control |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050267596A1 true US20050267596A1 (en) | 2005-12-01 |
Family
ID=35320703
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/122,315 Expired - Fee Related US8066780B2 (en) | 2004-05-03 | 2005-05-03 | Methods for gastric volume control |
US11/121,704 Abandoned US20050267596A1 (en) | 2004-05-03 | 2005-05-03 | Devices and systems for gastric volume control |
US12/504,468 Abandoned US20090275973A1 (en) | 2004-05-03 | 2009-07-16 | Devices and systems for gastric volume control |
US14/964,068 Abandoned US20160081831A1 (en) | 2004-05-03 | 2015-12-09 | Devices and systems for gastric volume control |
US14/964,119 Abandoned US20160095730A1 (en) | 2004-05-03 | 2015-12-09 | Devices and systems for gastric volume control |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/122,315 Expired - Fee Related US8066780B2 (en) | 2004-05-03 | 2005-05-03 | Methods for gastric volume control |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/504,468 Abandoned US20090275973A1 (en) | 2004-05-03 | 2009-07-16 | Devices and systems for gastric volume control |
US14/964,068 Abandoned US20160081831A1 (en) | 2004-05-03 | 2015-12-09 | Devices and systems for gastric volume control |
US14/964,119 Abandoned US20160095730A1 (en) | 2004-05-03 | 2015-12-09 | Devices and systems for gastric volume control |
Country Status (4)
Country | Link |
---|---|
US (5) | US8066780B2 (en) |
EP (1) | EP1744804A4 (en) |
JP (1) | JP4934024B2 (en) |
WO (1) | WO2005107641A2 (en) |
Cited By (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050261712A1 (en) * | 2004-04-26 | 2005-11-24 | Balbierz Daniel J | Restrictive and/or obstructive implant for inducing weight loss |
US20060142731A1 (en) * | 2004-12-27 | 2006-06-29 | Jeffrey Brooks | Floating gastro-intestinal anchor |
US20060142700A1 (en) * | 2003-06-20 | 2006-06-29 | Sobelman Owen S | Two-way slit valve |
US20070100367A1 (en) * | 2005-10-31 | 2007-05-03 | Quijano Rodolfo C | Intragastric space filler |
US20070100368A1 (en) * | 2005-10-31 | 2007-05-03 | Quijano Rodolfo C | Intragastric space filler |
US20070100369A1 (en) * | 2005-10-31 | 2007-05-03 | Cragg Andrew H | Intragastric space filler |
WO2007075978A3 (en) * | 2005-12-22 | 2007-11-29 | Wilson Cook Medical Inc | Coiled intragastric member for treating obesity |
US20070288033A1 (en) * | 2006-06-09 | 2007-12-13 | Allergan, Inc. | Intragastric balloon retrieval mechanisms |
US20080086082A1 (en) * | 2006-10-06 | 2008-04-10 | Brooks Jeffrey S | Radiopaque marking to detect balloon deflation |
US20080097510A1 (en) * | 2006-09-01 | 2008-04-24 | Albrecht Thomas E | Method for inducing weight loss with a patient |
US20080109027A1 (en) * | 2006-08-01 | 2008-05-08 | Fulfillium, Inc. | Method and system for gastric volume control |
US20080172079A1 (en) * | 2006-09-29 | 2008-07-17 | Allergan, Inc. | Apparatus and method for intragastric balloon with in situ adjustment means |
WO2008085290A2 (en) * | 2006-12-28 | 2008-07-17 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20080208241A1 (en) * | 2007-02-13 | 2008-08-28 | Brian Charles Weiner | Multi-method and multi-apparatus for treating obesity |
US20080255601A1 (en) * | 2007-04-13 | 2008-10-16 | Allergan, Inc. | Apparatus and method for remote deflation of intragastric balloon |
WO2008085291A3 (en) * | 2006-12-28 | 2008-10-23 | Vibrynt Inc | Devices and methods for treatment of obesity |
WO2009048496A1 (en) * | 2007-10-11 | 2009-04-16 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20090131968A1 (en) * | 2007-10-23 | 2009-05-21 | Allergan, Inc. | Pressure sensing intragastric balloon |
US20090275973A1 (en) * | 2004-05-03 | 2009-11-05 | Fulfillium, Inc. | Devices and systems for gastric volume control |
US20090298180A1 (en) * | 2008-05-30 | 2009-12-03 | Cattadoris Henry J | Cell culture apparatus and method |
US20100016871A1 (en) * | 2004-12-27 | 2010-01-21 | Spatz-Fgia, Inc. | Floating gastrointestinal anchor |
US20100049224A1 (en) * | 2007-03-29 | 2010-02-25 | Jaime Vargas | Intragastric Implant Devices |
WO2010042063A1 (en) * | 2008-10-10 | 2010-04-15 | Milux Holding S.A. | Apparatus for treating obesity |
US20100121371A1 (en) * | 2007-04-30 | 2010-05-13 | Spatz Fgia, Inc. | Non-endoscopic insertion and removal of a device |
US20100145138A1 (en) * | 2000-02-10 | 2010-06-10 | Obtech Medical Ag | Urinary incontinence treatment with wireless energy supply |
WO2010066761A1 (en) * | 2008-12-09 | 2010-06-17 | Compagnie Europeenne D'etude Et De Recherche De Dispositifs Pour L'implantation Par Laparoscopie | Implantable device with a multi-layer envelope, and corresponding method of production |
US20100168782A1 (en) * | 2008-12-27 | 2010-07-01 | John Hancock | High specific gravity intragastric device |
WO2010087757A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | Obesity treatment |
WO2010087772A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | An apparatus for treating gerd |
WO2010087773A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | An apparatus for treating gerd |
WO2010087774A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | Obesity treatment |
US7892292B2 (en) | 2001-08-27 | 2011-02-22 | Synecor, Llc | Positioning tools and methods for implanting medical devices |
US7909219B2 (en) | 2008-03-18 | 2011-03-22 | Barosense, Inc. | Endoscopic stapling devices and methods |
US20110092998A1 (en) * | 2009-10-13 | 2011-04-21 | Spatz Fgia, Inc. | Balloon hydraulic and gaseous expansion system |
US7934631B2 (en) | 2008-11-10 | 2011-05-03 | Barosense, Inc. | Multi-fire stapling systems and methods for delivering arrays of staples |
US7976554B2 (en) | 2006-04-19 | 2011-07-12 | Vibrynt, Inc. | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
EP2356956A1 (en) | 2006-03-28 | 2011-08-17 | Spatz-Fgia Inc. | Floating gastrointestinal anchor |
US8016851B2 (en) * | 2007-12-27 | 2011-09-13 | Cook Medical Technologies Llc | Delivery system and method of delivery for treating obesity |
US8029455B2 (en) | 2003-01-16 | 2011-10-04 | Barosense, Inc. | Satiation pouches and methods of use |
US8070768B2 (en) | 2006-04-19 | 2011-12-06 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
WO2011156176A1 (en) * | 2010-06-08 | 2011-12-15 | Regents Of The University Of Minnesota | Vascular elastance |
US8096938B2 (en) | 1999-08-12 | 2012-01-17 | Obtech Medical Ag | Controlled anal incontinence disease treatment |
US8109895B2 (en) | 2006-09-02 | 2012-02-07 | Barosense, Inc. | Intestinal sleeves and associated deployment systems and methods |
US8126558B2 (en) | 2000-02-14 | 2012-02-28 | Obtech Medical Ag | Controlled penile prosthesis |
EP2401991A3 (en) * | 2006-07-24 | 2012-03-21 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8142469B2 (en) | 2007-06-25 | 2012-03-27 | Reshape Medical, Inc. | Gastric space filler device, delivery system, and related methods |
US20120123465A1 (en) * | 2009-03-31 | 2012-05-17 | Raj Nihalani | Method and apparatus for treating obesity and controlling weight gain using self-expanding intragastric devices |
US8187297B2 (en) | 2006-04-19 | 2012-05-29 | Vibsynt, Inc. | Devices and methods for treatment of obesity |
US8192455B2 (en) | 2003-08-13 | 2012-06-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compressive device for percutaneous treatment of obesity |
US8206456B2 (en) | 2003-10-10 | 2012-06-26 | Barosense, Inc. | Restrictive and/or obstructive implant system for inducing weight loss |
WO2012054411A3 (en) * | 2010-10-19 | 2012-06-28 | Allergan, Inc. | Upper stomach gastric implants |
US8226602B2 (en) | 2007-03-30 | 2012-07-24 | Reshape Medical, Inc. | Intragastric balloon system and therapeutic processes and products |
WO2012054410A3 (en) * | 2010-10-19 | 2012-08-02 | Allergan, Inc. | Intragastric implants with multiple fluid chambers |
US8290594B2 (en) | 2000-02-11 | 2012-10-16 | Obtech Medical Ag | Impotence treatment apparatus with energy transforming means |
US8287444B2 (en) | 2000-02-10 | 2012-10-16 | Obtech Medical Ag | Mechanical impotence treatment apparatus |
US8313423B2 (en) | 2000-02-14 | 2012-11-20 | Peter Forsell | Hydraulic anal incontinence treatment |
US8337566B2 (en) | 2002-04-08 | 2012-12-25 | Barosense, Inc. | Method and apparatus for modifying the exit orifice of a satiation pouch |
US8382775B1 (en) | 2012-01-08 | 2013-02-26 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
WO2013039412A1 (en) * | 2011-09-14 | 2013-03-21 | PULSMED sp. zo.o. | The method of filling an intragastric balloon |
US8469977B2 (en) | 2005-10-03 | 2013-06-25 | Barosense, Inc. | Endoscopic plication device and method |
US8509894B2 (en) | 2008-10-10 | 2013-08-13 | Milux Holding Sa | Heart help device, system, and method |
US8545384B2 (en) | 1999-08-12 | 2013-10-01 | Obtech Medical Ag | Anal incontinence disease treatment with controlled wireless energy supply |
US8556796B2 (en) | 2000-02-10 | 2013-10-15 | Obtech Medical Ag | Controlled urinary incontinence treatment |
US8568648B2 (en) | 2005-12-16 | 2013-10-29 | Interface Associates, Inc. | Methods for manufacturing multi-layer balloons for medical applications |
US8568488B2 (en) | 2001-08-27 | 2013-10-29 | Boston Scientific Scimed, Inc. | Satiation devices and methods |
US8585733B2 (en) | 2006-04-19 | 2013-11-19 | Vibrynt, Inc | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US8600510B2 (en) | 2008-10-10 | 2013-12-03 | Milux Holding Sa | Apparatus, system and operation method for the treatment of female sexual dysfunction |
US8678997B2 (en) | 2000-02-14 | 2014-03-25 | Obtech Medical Ag | Male impotence prosthesis apparatus with wireless energy supply |
US8683881B2 (en) | 2009-04-03 | 2014-04-01 | Reshape Medical, Inc. | Intragastric space fillers and methods of manufacturing including in vitro testing |
US8696745B2 (en) | 2008-10-10 | 2014-04-15 | Kirk Promotion Ltd. | Heart help device, system, and method |
US8734318B2 (en) | 2000-02-11 | 2014-05-27 | Obtech Medical Ag | Mechanical anal incontinence |
US8764627B2 (en) | 2000-02-14 | 2014-07-01 | Obtech Medical Ag | Penile prosthesis |
US8784500B2 (en) | 2003-10-10 | 2014-07-22 | Boston Scientific Scimed, Inc. | Devices and methods for retaining a gastro-esophageal implant |
US8845672B2 (en) | 2002-05-09 | 2014-09-30 | Reshape Medical, Inc. | Balloon system and methods for treating obesity |
US8864840B2 (en) | 2010-10-19 | 2014-10-21 | Apollo Endosurgery, Inc. | Intragastric implants with collapsible frames |
US8874215B2 (en) | 2008-10-10 | 2014-10-28 | Peter Forsell | System, an apparatus, and a method for treating a sexual dysfunctional female patient |
US8870966B2 (en) | 2010-10-18 | 2014-10-28 | Apollo Endosurgery, Inc. | Intragastric balloon for treating obesity |
US8876850B1 (en) | 2014-06-19 | 2014-11-04 | Aria Cv, Inc. | Systems and methods for treating pulmonary hypertension |
US8888732B2 (en) | 2011-03-11 | 2014-11-18 | Apollo Endosurgery, Inc. | Intraluminal sleeve with active agents |
US8894568B2 (en) | 2009-09-24 | 2014-11-25 | Reshape Medical, Inc. | Normalization and stabilization of balloon surfaces for deflation |
US8920447B2 (en) | 2010-10-19 | 2014-12-30 | Apollo Endosurgery, Inc. | Articulated gastric implant clip |
US8945167B2 (en) | 2007-12-31 | 2015-02-03 | Boston Scientific Scimed, Inc. | Gastric space occupier systems and methods of use |
US8956380B2 (en) | 2010-10-18 | 2015-02-17 | Apollo Endosurgery, Inc. | Reactive intragastric implant devices |
US8961448B2 (en) | 2008-01-28 | 2015-02-24 | Peter Forsell | Implantable drainage device |
US8961539B2 (en) | 2009-05-04 | 2015-02-24 | Boston Scientific Scimed, Inc. | Endoscopic implant system and method |
US9017359B2 (en) | 2010-11-22 | 2015-04-28 | Aria Cv, Inc. | System and method for reducing pulsatile pressure |
US9050174B2 (en) | 2009-07-23 | 2015-06-09 | Reshape Medical, Inc. | Deflation and removal of implantable medical devices |
US9072579B2 (en) | 2009-10-21 | 2015-07-07 | Apollo Endosurgery, Inc. | Bariatric device and method for weight loss |
US9095405B2 (en) | 2010-10-19 | 2015-08-04 | Apollo Endosurgery, Inc. | Space-filling intragastric implants with fluid flow |
US9107727B2 (en) | 2001-08-27 | 2015-08-18 | Boston Scientific Scimed, Inc. | Satiation devices and methods |
US9149611B2 (en) | 2010-02-08 | 2015-10-06 | Reshape Medical, Inc. | Materials and methods for improved intragastric balloon devices |
US9155650B2 (en) | 2010-03-15 | 2015-10-13 | Apollo Endosurgery, Inc. | Bariatric device and method for weight loss |
US9173734B2 (en) | 2009-09-29 | 2015-11-03 | IBIS Medical, Inc. | Intragastric implant devices |
US9174031B2 (en) | 2009-03-13 | 2015-11-03 | Reshape Medical, Inc. | Device and method for deflation and removal of implantable and inflatable devices |
US9192501B2 (en) | 2010-04-30 | 2015-11-24 | Apollo Endosurgery, Inc. | Remotely powered remotely adjustable gastric band system |
US9233016B2 (en) | 2010-10-18 | 2016-01-12 | Apollo Endosurgery, Inc. | Elevating stomach stimulation device |
US9314361B2 (en) | 2006-09-15 | 2016-04-19 | Boston Scientific Scimed, Inc. | System and method for anchoring stomach implant |
US9314362B2 (en) | 2012-01-08 | 2016-04-19 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
US9358143B2 (en) | 2009-07-22 | 2016-06-07 | Reshape Medical, Inc. | Retrieval mechanisms for implantable medical devices |
US9398969B2 (en) | 2010-10-19 | 2016-07-26 | Apollo Endosurgery, Inc. | Upper stomach gastric implants |
US9445930B2 (en) | 2004-11-19 | 2016-09-20 | Fulfillium, Inc. | Methods, devices, and systems for obesity treatment |
US9456915B2 (en) | 2004-11-19 | 2016-10-04 | Fulfilium, Inc. | Methods, devices, and systems for obesity treatment |
US9456825B2 (en) | 2007-07-18 | 2016-10-04 | Boston Scientific Scimed, Inc. | Endoscopic implant system and method |
US9463107B2 (en) | 2010-10-18 | 2016-10-11 | Apollo Endosurgery, Inc. | Variable size intragastric implant devices |
WO2016172054A1 (en) * | 2015-04-23 | 2016-10-27 | Obalon Therapeutics, Inc. | Systems and methods for preventing passage of intragastric devices |
US9545249B2 (en) | 2007-07-18 | 2017-01-17 | Boston Scientific Scimed, Inc. | Overtube introducer for use in endoscopic bariatric surgery |
US9604038B2 (en) | 2009-07-23 | 2017-03-28 | Reshape Medical, Inc. | Inflation and deflation mechanisms for inflatable medical devices |
US9622896B2 (en) | 2010-02-08 | 2017-04-18 | Reshape Medical, Inc. | Enhanced aspiration processes and mechanisms for instragastric devices |
US9629740B2 (en) | 2010-04-06 | 2017-04-25 | Reshape Medical, Inc. | Inflation devices for intragastric devices with improved attachment and detachment and associated systems and methods |
US9668901B2 (en) | 2010-10-18 | 2017-06-06 | Apollo Endosurgery Us, Inc. | Intragastric implants with duodenal anchors |
US9681973B2 (en) | 2010-02-25 | 2017-06-20 | Reshape Medical, Inc. | Enhanced explant processes and mechanisms for intragastric devices |
US9949812B2 (en) | 2009-07-17 | 2018-04-24 | Peter Forsell | Vaginal operation method for the treatment of anal incontinence in women |
US9974680B2 (en) | 2004-12-27 | 2018-05-22 | Spatz Fgia, Inc. | System and methods for internalization of external components of adjustable intragastric balloon |
US10070980B2 (en) | 2010-10-19 | 2018-09-11 | Apollo Endosurgery Us, Inc. | Anchored non-piercing duodenal sleeve and delivery systems |
US10137023B2 (en) | 2012-09-14 | 2018-11-27 | Medibotics Llc | Colonnade (TM) expandable intragastric food flow lumen device |
US10219898B2 (en) | 2008-10-10 | 2019-03-05 | Peter Forsell | Artificial valve |
US20200069923A1 (en) * | 2018-08-29 | 2020-03-05 | Jonathan SOVEROW | Angioplasty balloon snare |
US10857019B2 (en) | 2012-11-26 | 2020-12-08 | Spatz Fgia, Inc. | System and methods for internalization of external components of an adjustable intragastric balloon |
US10893966B2 (en) | 2017-02-09 | 2021-01-19 | Spatz FGIA Ltd | Check valve with docking station for gastrointestinal balloon |
WO2021030632A1 (en) * | 2019-08-13 | 2021-02-18 | Transit Scientific, LLC | Exoskeleton device with expandable section for scoring |
US10952836B2 (en) | 2009-07-17 | 2021-03-23 | Peter Forsell | Vaginal operation method for the treatment of urinary incontinence in women |
US11123171B2 (en) | 2008-10-10 | 2021-09-21 | Peter Forsell | Fastening means for implantable medical control assembly |
US11141581B2 (en) | 2019-09-06 | 2021-10-12 | Aria Cv, Inc. | Diffusion and infusion resistant implantable devices for reducing pulsatile pressure |
US11179549B2 (en) | 2017-10-27 | 2021-11-23 | Transit Scientific, LLC | Exoskeleton device with expandable section for scoring |
US11331105B2 (en) | 2016-10-19 | 2022-05-17 | Aria Cv, Inc. | Diffusion resistant implantable devices for reducing pulsatile pressure |
US11406801B2 (en) | 2017-10-27 | 2022-08-09 | Transit Scientific, LLC | Exoskeleton device with expandable section for scoring |
US11950778B2 (en) | 2010-05-21 | 2024-04-09 | Boston Scientific Scimed, Inc. | Tissue-acquisition and fastening devices and methods |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7837669B2 (en) | 2002-11-01 | 2010-11-23 | Valentx, Inc. | Devices and methods for endolumenal gastrointestinal bypass |
US9060844B2 (en) | 2002-11-01 | 2015-06-23 | Valentx, Inc. | Apparatus and methods for treatment of morbid obesity |
US8585771B2 (en) * | 2004-02-26 | 2013-11-19 | Endosphere, Inc. | Methods and devices to curb appetite and/or to reduce food intake |
US8147561B2 (en) | 2004-02-26 | 2012-04-03 | Endosphere, Inc. | Methods and devices to curb appetite and/or reduce food intake |
US20060142790A1 (en) * | 2004-03-23 | 2006-06-29 | Michael Gertner | Methods and devices to facilitate connections between body lumens |
US20070233170A1 (en) * | 2004-03-23 | 2007-10-04 | Michael Gertner | Extragastric Balloon |
US7255675B2 (en) * | 2004-03-23 | 2007-08-14 | Michael Gertner | Devices and methods to treat a patient |
WO2006049725A2 (en) | 2004-03-23 | 2006-05-11 | Minimus Surgical Systems | Surgical systems and devices to enhance gastric restriction therapies |
US7946976B2 (en) | 2004-03-23 | 2011-05-24 | Michael Gertner | Methods and devices for the surgical creation of satiety and biofeedback pathways |
WO2005110280A2 (en) | 2004-05-07 | 2005-11-24 | Valentx, Inc. | Devices and methods for attaching an endolumenal gastrointestinal implant |
AU2005286840B2 (en) * | 2004-09-21 | 2012-01-12 | Shalon Ventures, Inc. | Tissue expansion devices |
US20080161717A1 (en) * | 2005-05-10 | 2008-07-03 | Michael Eric Gertner | Obesity Treatment Systems |
AU2006257892A1 (en) * | 2005-06-10 | 2006-12-21 | Novalert, Inc. | Method and apparatus for monitoring implants |
US8740988B1 (en) * | 2005-06-16 | 2014-06-03 | Robert L. Hively | Bariatric balloon apparatus |
US8216266B2 (en) * | 2005-06-16 | 2012-07-10 | Hively Robert L | Gastric bariatric apparatus with selective inflation and safety features |
JP4777017B2 (en) * | 2005-08-24 | 2011-09-21 | オリンパスメディカルシステムズ株式会社 | Intragastric balloon and balloon medium |
EP1948077B1 (en) * | 2005-10-31 | 2015-12-23 | ReShape Medical Corporation | Intragastric space filler |
US8216268B2 (en) | 2005-12-22 | 2012-07-10 | Cook Medical Technologies Llc | Intragastric bag for treating obesity |
WO2007127209A2 (en) | 2006-04-25 | 2007-11-08 | Valentx, Inc. | Methods and devices for gastrointestinal stimulation |
US20090012372A1 (en) * | 2006-06-12 | 2009-01-08 | Novalert, Inc. | External sensing for implant rupture |
US7914511B2 (en) * | 2006-10-18 | 2011-03-29 | Ethicon Endo-Surgery, Inc. | Use of biosurgical adhesive as bulking agent |
US20080146869A1 (en) * | 2006-10-30 | 2008-06-19 | Hector Chow | Adjustable Gastric Band Having Anti-Microbial Coatings |
US20090082644A1 (en) * | 2007-03-15 | 2009-03-26 | Jiayi Li | Devices, Systems, Kits and Methods for Treatment of Obesity |
DE102007025312A1 (en) * | 2007-05-25 | 2008-11-27 | Q Medical International Ag | Intragastric stomach use for the treatment of obesity |
WO2008154450A1 (en) * | 2007-06-08 | 2008-12-18 | Valentx, Inc. | Methods and devices for intragastric support of functional or prosthetic gastrointestinal devices |
WO2010045482A2 (en) | 2008-10-16 | 2010-04-22 | Obalon Therapeutics, Inc. | Intragastric device |
BR112012013276A2 (en) * | 2009-12-01 | 2019-09-24 | Stuart David | rupture detection system, device for detecting discontinuity in a breast implant, method for detecting discontinuity in a breast implant breast |
ES2556806T3 (en) * | 2009-12-18 | 2016-01-20 | Airxpanders, Inc. | Tissue expanders |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
PT2665512T (en) | 2011-01-21 | 2016-08-29 | Obalon Therapeutics Inc | Intragastric device |
US8647358B2 (en) | 2011-01-21 | 2014-02-11 | Obalon Therapeutics Inc. | Intragastric device |
US8292911B2 (en) | 2011-01-21 | 2012-10-23 | Obalon Therapeutics, Inc. | Intragastric device |
US8202291B1 (en) | 2011-01-21 | 2012-06-19 | Obalon Therapeutics, Inc. | Intragastric device |
US20120296365A1 (en) * | 2011-05-17 | 2012-11-22 | Endobese, Inc. | Method and Apparatus for Buoyant Gastric Implant |
US8986337B2 (en) * | 2012-02-24 | 2015-03-24 | Elwha Llc | Devices, systems, and methods to control stomach volume |
WO2013181034A1 (en) * | 2012-05-30 | 2013-12-05 | Hollstien David S | Breast implant with shell failure detection |
US20130324906A1 (en) | 2012-05-31 | 2013-12-05 | Valen Tx, Inc. | Devices and methods for gastrointestinal bypass |
US9681975B2 (en) | 2012-05-31 | 2017-06-20 | Valentx, Inc. | Devices and methods for gastrointestinal bypass |
US9173759B2 (en) | 2012-05-31 | 2015-11-03 | Valentx, Inc. | Devices and methods for gastrointestinal bypass |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
US9277905B2 (en) | 2012-08-02 | 2016-03-08 | W. L. Gore & Associates, Inc. | Space-filling device |
US9463106B2 (en) | 2012-09-10 | 2016-10-11 | Boston Scientific Scimed, Inc. | Catheter with releasable balloon and related methods |
US10028857B2 (en) * | 2013-02-15 | 2018-07-24 | Convatec Technologies Inc | Methods and systems for ostomy care |
EP3954286A1 (en) | 2013-02-21 | 2022-02-16 | Airxpanders, Inc. | Implantable tissue expanders |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US9757264B2 (en) | 2013-03-13 | 2017-09-12 | Valentx, Inc. | Devices and methods for gastrointestinal bypass |
US10264995B2 (en) | 2013-12-04 | 2019-04-23 | Obalon Therapeutics, Inc. | Systems and methods for locating and/or characterizing intragastric devices |
US9895248B2 (en) | 2014-10-09 | 2018-02-20 | Obalon Therapeutics, Inc. | Ultrasonic systems and methods for locating and/or characterizing intragastric devices |
US9687375B2 (en) * | 2015-03-17 | 2017-06-27 | Shahriar Sedghi | Magnetic satiety-inducing system |
US9925081B2 (en) * | 2015-03-17 | 2018-03-27 | Shahriar Sedghi | Magnetic satiety inducing system |
WO2016171763A1 (en) | 2015-04-23 | 2016-10-27 | Obalon Therapeutics, Inc. | Systems and methods for determining failure of intragastric devices |
BR112017024064B1 (en) | 2015-06-11 | 2022-09-27 | Obalon Therapeutics, Inc | DISPENSER AND INTRAGASTRIC BALLOON SYSTEM |
US10335303B2 (en) | 2015-12-07 | 2019-07-02 | Obalon Therapeutics, Inc. | Intragastric device |
US10537453B2 (en) | 2015-12-16 | 2020-01-21 | Obalon Therapeutics, Inc. | Intragastric device with expandable portions |
US10238798B2 (en) * | 2016-03-22 | 2019-03-26 | Novartis Ag | Pressurizable fluid supply apparatus |
US10350100B2 (en) | 2016-04-12 | 2019-07-16 | Obalon Therapeutics, Inc. | System for detecting an intragastric balloon |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10772752B2 (en) | 2016-11-04 | 2020-09-15 | Obalon Therapeutics, Inc. | Pressure control system for intragastric device |
KR102200454B1 (en) * | 2018-08-07 | 2021-01-08 | 재단법인 아산사회복지재단 | Implantable medical device, medical system and medical kit |
KR102163651B1 (en) * | 2018-12-24 | 2020-10-08 | 박용희 | using buoy system for dirt |
CN110420005B (en) * | 2019-08-09 | 2021-09-28 | 上海市第一人民医院 | Expandable miniature gastroscope robot with telescopic arm and field planting function |
CN113384391B (en) * | 2021-06-30 | 2022-07-12 | 甘肃省人民医院 | Controllable stoma belt cleaning device of flow |
Citations (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3046988A (en) * | 1958-12-01 | 1962-07-31 | Davol Rubber Co | Esophageal nasogastric tube |
US3055371A (en) * | 1958-12-23 | 1962-09-25 | Kulick George | Device for regulation and control of esophago-gastric balloons |
US3906959A (en) * | 1974-02-14 | 1975-09-23 | American Optical Corp | Liquid leak stop for an implantable heart pacer |
US4133315A (en) * | 1976-12-27 | 1979-01-09 | Berman Edward J | Method and apparatus for reducing obesity |
US4246893A (en) * | 1978-07-05 | 1981-01-27 | Daniel Berson | Inflatable gastric device for treating obesity |
US4311146A (en) * | 1980-05-08 | 1982-01-19 | Sorenson Research Co., Inc. | Detachable balloon catheter apparatus and method |
US4416267A (en) * | 1981-12-10 | 1983-11-22 | Garren Lloyd R | Method and apparatus for treating obesity |
US4485805A (en) * | 1982-08-24 | 1984-12-04 | Gunther Pacific Limited Of Hong Kong | Weight loss device and method |
US4501264A (en) * | 1978-06-02 | 1985-02-26 | Rockey Arthur G | Medical sleeve |
US4557640A (en) * | 1978-03-13 | 1985-12-10 | Rottler Donald B | Combination boring and honing apparatus and method |
US4607618A (en) * | 1983-02-23 | 1986-08-26 | Angelchik Jean P | Method for treatment of morbid obesity |
US4648383A (en) * | 1985-01-11 | 1987-03-10 | Angelchik Jean P | Peroral apparatus for morbid obesity treatment |
US4694827A (en) * | 1986-01-14 | 1987-09-22 | Weiner Brian C | Inflatable gastric device for treating obesity and method of using the same |
US4723893A (en) * | 1985-07-10 | 1988-02-09 | 501 Komatsu Zenoah Company | Portable blower |
US4739758A (en) * | 1986-05-19 | 1988-04-26 | Criticare Systems, Inc. | Apparatus for stomach cavity reduction |
US4795463A (en) * | 1984-10-03 | 1989-01-03 | Baylor College Of Medicine | Labeled breast prosthesis and methods for detecting and predicting rupture of the prosthesis |
US4899747A (en) * | 1981-12-10 | 1990-02-13 | Garren Lloyd R | Method and appartus for treating obesity |
US4908011A (en) * | 1986-05-22 | 1990-03-13 | Ballobes Aps | Method and device for performing a puncturing work on an inflated balloon-like object implanted in a patient |
US4983167A (en) * | 1988-11-23 | 1991-01-08 | Harvinder Sahota | Balloon catheters |
US5084061A (en) * | 1987-09-25 | 1992-01-28 | Gau Fred C | Intragastric balloon with improved valve locating means |
US5160321A (en) * | 1988-11-23 | 1992-11-03 | Harvinder Sahota | Balloon catheters |
US5234454A (en) * | 1991-08-05 | 1993-08-10 | Akron City Hospital | Percutaneous intragastric balloon catheter and method for controlling body weight therewith |
US5259399A (en) * | 1992-03-02 | 1993-11-09 | Alan Brown | Device and method of causing weight loss using removable variable volume intragastric bladder |
US5476005A (en) * | 1993-07-09 | 1995-12-19 | Siemens Elema Ab | Method and apparatus for tracing leaks in vivo occurring in an electrode device of an implanted medical apparatus |
US5501667A (en) * | 1994-03-15 | 1996-03-26 | Cordis Corporation | Perfusion balloon and method of use and manufacture |
US5579765A (en) * | 1995-05-30 | 1996-12-03 | Cox; Danny L. | Monitor to detect bleeding |
US5833603A (en) * | 1996-03-13 | 1998-11-10 | Lipomatrix, Inc. | Implantable biosensing transponder |
US5865801A (en) * | 1995-07-18 | 1999-02-02 | Houser; Russell A. | Multiple compartmented balloon catheter with external pressure sensing |
US5993473A (en) * | 1997-11-19 | 1999-11-30 | Chan; Yung C. | Expandable body device for the gastric cavity and method |
US20010010024A1 (en) * | 1987-12-22 | 2001-07-26 | Ledergerber Walter J. | Tissue expander |
US6272914B1 (en) * | 1998-08-05 | 2001-08-14 | Freni Brembo, S.P.A. | Device for indicating caliper pad wear in disc brakes |
US20020055757A1 (en) * | 2000-11-03 | 2002-05-09 | Torre Roger De La | Method and device for use in minimally invasive placement of intragastric devices |
US6427089B1 (en) * | 1999-02-19 | 2002-07-30 | Edward W. Knowlton | Stomach treatment apparatus and method |
US6454785B2 (en) * | 2000-02-24 | 2002-09-24 | DE HOYOS GARZA ANDRéS | Percutaneous intragastric balloon catheter for the treatment of obesity |
US6579301B1 (en) * | 2000-11-17 | 2003-06-17 | Syntheon, Llc | Intragastric balloon device adapted to be repeatedly varied in volume without external assistance |
US20030171768A1 (en) * | 2002-03-07 | 2003-09-11 | Mcghan Jim J. | Self-deflating intragastric balloon |
US6634216B1 (en) * | 1998-07-10 | 2003-10-21 | Joven Denki Kabushiki Kaisha | Inspection method for sealed package |
US6647762B1 (en) * | 1998-03-05 | 2003-11-18 | Palmer Environmental Limited | Detecting leaks in pipes |
US6656194B1 (en) * | 2002-11-05 | 2003-12-02 | Satiety, Inc. | Magnetic anchoring devices |
US20040044357A1 (en) * | 2002-08-30 | 2004-03-04 | James Gannoe | Stented anchoring of gastric space-occupying devices |
US20040059289A1 (en) * | 2001-03-09 | 2004-03-25 | Jose Rafael Garza Alvarez | Intragastric balloon assembly |
US6736793B2 (en) * | 1999-02-02 | 2004-05-18 | Ams Research Corporation | Self-sealing detachable balloon |
US20040102712A1 (en) * | 2002-11-25 | 2004-05-27 | Andres Belalcazar | Impedance monitoring for detecting pulmonary edema and thoracic congestion |
US20040106899A1 (en) * | 2002-11-30 | 2004-06-03 | Mcmichael Donald J. | Gastric balloon catheter with improved balloon orientation |
US6746460B2 (en) * | 2002-08-07 | 2004-06-08 | Satiety, Inc. | Intra-gastric fastening devices |
US20040122526A1 (en) * | 2002-12-23 | 2004-06-24 | Imran Mir A. | Stomach prosthesis |
US20040186502A1 (en) * | 2003-03-19 | 2004-09-23 | Sampson Douglas C. | Self-Inflating intragastric volume-occupying device |
US20040186503A1 (en) * | 2003-03-17 | 2004-09-23 | Delegge Rebecca | Intragastric catheter |
US20050033331A1 (en) * | 2003-07-28 | 2005-02-10 | Polymorfix, Inc., C/O Medventure Associates | Pyloric valve obstructing devices and methods |
US20050055039A1 (en) * | 2003-07-28 | 2005-03-10 | Polymorfix, Inc. | Devices and methods for pyloric anchoring |
US20050107664A1 (en) * | 2000-03-24 | 2005-05-19 | Kalloo Anthony N. | Methods and devices for diagnostic and therapeutic interventions in the peritoneal cavity |
US20050149186A1 (en) * | 2003-02-06 | 2005-07-07 | Rfs Health Sciences, Inc. | Cosmetic and reconstructive prosthesis containing a biologically compatible rupture indicator |
US20050181977A1 (en) * | 2003-11-10 | 2005-08-18 | Angiotech International Ag | Medical implants and anti-scarring agents |
US20050192614A1 (en) * | 2004-02-26 | 2005-09-01 | Binmoeller Kenneth F. | Method and apparatus for reducing obesity |
US20050273060A1 (en) * | 2004-06-03 | 2005-12-08 | Mayo Foundation For Medical Education And Research | Obesity treatment and device |
US20060004272A1 (en) * | 2003-11-13 | 2006-01-05 | Rajiv Shah | Long term analyte sensor array |
US7066945B2 (en) * | 2001-05-17 | 2006-06-27 | Wilson-Cook Medical Inc. | Intragastric device for treating obesity |
US20060178691A1 (en) * | 2004-02-26 | 2006-08-10 | Binmoeller Kenneth F | Methods and devices to curb appetite and/or reduce food intake |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK13881A (en) | 1981-01-14 | 1982-07-15 | O G Nien | PROCEDURE AND APPARATUS FOR DEFINITION INFLUENCE AND LEAVE OF A FOREIGN SUBSTANCE IN HUMAN BAG |
DE3206118A1 (en) | 1982-02-19 | 1983-11-03 | J.J. McCloy - K.C. Eicke Ltd., London | DEVICE FOR REDUCING THE STOMACH RESERVOIR WITH AN INTRAGASTRAL APPLICABLE CUSHION |
EP0103481A1 (en) | 1982-09-14 | 1984-03-21 | Ainsworth Nominees Proprietary Limited | Treatment and reduction of obesity in humans |
WO1988000027A1 (en) | 1986-07-09 | 1988-01-14 | Angelchik Jean P | Method for treatment of morbid obesity |
GB2139902B (en) | 1983-05-17 | 1986-12-31 | Louis Roger Celestin | Balloon introducer apparatus |
US4577640A (en) | 1984-03-20 | 1986-03-25 | Hofmeister John F | Method and apparatus for direct in vivo monitoring of uterine electrical activity |
US4598699A (en) * | 1985-06-10 | 1986-07-08 | Garren Lloyd R | Endoscopic instrument for removing stomach insert |
GB8517092D0 (en) | 1985-07-05 | 1985-08-14 | Taylor T V | Artificial bezoar |
IL78883A0 (en) | 1986-05-23 | 1986-09-30 | Omikron Scient Ltd | Device and method for treating a patient for obesity |
JPS63264078A (en) * | 1987-04-22 | 1988-10-31 | オリンパス光学工業株式会社 | Balloon for diet |
JPH03277374A (en) * | 1990-03-28 | 1991-12-09 | Create Medic Kk | Improved balloon catheter for medical treatment |
US5308317A (en) * | 1990-06-07 | 1994-05-03 | Arch Development Corporation | Protective tube laser endoscopy |
US5400770A (en) * | 1992-01-15 | 1995-03-28 | Nakao; Naomi L. | Device utilizable with endoscope and related method |
US5401241A (en) * | 1992-05-07 | 1995-03-28 | Inamed Development Co. | Duodenal intubation catheter |
US5653683A (en) * | 1995-02-28 | 1997-08-05 | D'andrea; Mark A. | Intracavitary catheter for use in therapeutic radiation procedures |
AU705933B2 (en) * | 1995-06-02 | 1999-06-03 | Pioneer Hi-Bred International, Inc. | High threonine derivatives of alpha-hordothionin |
DE69821342T2 (en) * | 1997-04-07 | 2004-12-02 | Cook Urological Inc., Spencer | SECURED BRACKET FOR A DRAINAGE CATHETER |
US6855143B2 (en) * | 1997-06-13 | 2005-02-15 | Arthrocare Corporation | Electrosurgical systems and methods for recanalization of occluded body lumens |
US6057689A (en) * | 1997-08-04 | 2000-05-02 | Gynecare, Inc. | Apparatus and method for leak detection in a fluid-filled balloon useful to treat body tissue |
US20010020150A1 (en) * | 1998-02-06 | 2001-09-06 | Biagio Ravo | Inflatable intraluminal molding device |
US6988983B2 (en) * | 2000-04-14 | 2006-01-24 | Solace Therapeutics, Inc. | Implantable self-inflating attenuation device |
JP3464642B2 (en) * | 2000-06-13 | 2003-11-10 | 松下電器産業株式会社 | Synchronization acquisition device and synchronization acquisition method |
JP3977983B2 (en) | 2000-07-31 | 2007-09-19 | 株式会社タニタ | Dehydration state determination device by bioimpedance measurement |
JP4674006B2 (en) * | 2001-07-10 | 2011-04-20 | オリンパス株式会社 | Endoscope |
US6605056B2 (en) * | 2001-07-11 | 2003-08-12 | Scimed Life Systems, Inc. | Conformable balloon |
US6755869B2 (en) * | 2001-11-09 | 2004-06-29 | Boston Scientific Corporation | Intragastric prosthesis for the treatment of morbid obesity |
FR2834202B1 (en) | 2001-12-28 | 2004-03-19 | Cie Euro Etude Rech Paroscopie | MULTI-POCKET INTRA-GASTRIC BALLOON, SURGICAL EXPANSION DEVICE FOR SAID BALLOON AND MANUFACTURING METHOD THEREOF |
US20030153905A1 (en) * | 2002-01-25 | 2003-08-14 | Edwards Stuart Denzil | Selective ablation system |
GB2384993B (en) | 2002-02-06 | 2004-05-12 | David Alan Burt | Medical surgeons detection aid |
DE60328476D1 (en) | 2002-05-09 | 2009-09-03 | Reshape Medical | MEDICAL BALLOON SYSTEM FOR THE TREATMENT OF ADIPOSITAS |
US20050261719A1 (en) * | 2002-11-25 | 2005-11-24 | Israel Chermoni | Catheter and method of its use |
US7141071B2 (en) * | 2002-12-23 | 2006-11-28 | Python Medical, Inc. | Implantable digestive tract organ |
FR2852821B1 (en) * | 2003-03-31 | 2007-06-01 | Cie Euro Etude Rech Paroscopie | PARYLENE-COATED INTRA-GASTRIC BALLOON, PROCESS FOR PRODUCING SUCH BALLOON AND USE OF PARYLENE FOR COATING INTRA-GASTRIC BALLOON |
US7041080B2 (en) * | 2003-08-01 | 2006-05-09 | Medtronic Vascular, Inc. | Rotary valve for balloon catheter |
US7303574B2 (en) * | 2003-08-07 | 2007-12-04 | Medtronic Vasculor, Inc. | Occlusion catheter with frictional valve |
US8192455B2 (en) * | 2003-08-13 | 2012-06-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compressive device for percutaneous treatment of obesity |
US20050070937A1 (en) * | 2003-09-30 | 2005-03-31 | Jambor Kristin L. | Segmented gastric band |
WO2005039458A2 (en) * | 2003-10-23 | 2005-05-06 | Proxy Biomedical Limited | “a gastric constriction device” |
US7261730B2 (en) * | 2003-11-14 | 2007-08-28 | Lumerx, Inc. | Phototherapy device and system |
EP1744804A4 (en) * | 2004-05-03 | 2009-11-04 | Fulfillium Inc | Method and system for gastric volume control |
US7112186B2 (en) * | 2004-05-26 | 2006-09-26 | Shah Tilak M | Gastro-occlusive device |
US20070100369A1 (en) * | 2005-10-31 | 2007-05-03 | Cragg Andrew H | Intragastric space filler |
-
2005
- 2005-05-03 EP EP05749678A patent/EP1744804A4/en not_active Withdrawn
- 2005-05-03 US US11/122,315 patent/US8066780B2/en not_active Expired - Fee Related
- 2005-05-03 JP JP2007511542A patent/JP4934024B2/en not_active Expired - Fee Related
- 2005-05-03 WO PCT/US2005/015498 patent/WO2005107641A2/en active Application Filing
- 2005-05-03 US US11/121,704 patent/US20050267596A1/en not_active Abandoned
-
2009
- 2009-07-16 US US12/504,468 patent/US20090275973A1/en not_active Abandoned
-
2015
- 2015-12-09 US US14/964,068 patent/US20160081831A1/en not_active Abandoned
- 2015-12-09 US US14/964,119 patent/US20160095730A1/en not_active Abandoned
Patent Citations (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3046988A (en) * | 1958-12-01 | 1962-07-31 | Davol Rubber Co | Esophageal nasogastric tube |
US3055371A (en) * | 1958-12-23 | 1962-09-25 | Kulick George | Device for regulation and control of esophago-gastric balloons |
US3906959A (en) * | 1974-02-14 | 1975-09-23 | American Optical Corp | Liquid leak stop for an implantable heart pacer |
US4133315A (en) * | 1976-12-27 | 1979-01-09 | Berman Edward J | Method and apparatus for reducing obesity |
US4557640A (en) * | 1978-03-13 | 1985-12-10 | Rottler Donald B | Combination boring and honing apparatus and method |
US4501264A (en) * | 1978-06-02 | 1985-02-26 | Rockey Arthur G | Medical sleeve |
US4246893A (en) * | 1978-07-05 | 1981-01-27 | Daniel Berson | Inflatable gastric device for treating obesity |
US4311146A (en) * | 1980-05-08 | 1982-01-19 | Sorenson Research Co., Inc. | Detachable balloon catheter apparatus and method |
US4899747A (en) * | 1981-12-10 | 1990-02-13 | Garren Lloyd R | Method and appartus for treating obesity |
US4416267A (en) * | 1981-12-10 | 1983-11-22 | Garren Lloyd R | Method and apparatus for treating obesity |
US4485805A (en) * | 1982-08-24 | 1984-12-04 | Gunther Pacific Limited Of Hong Kong | Weight loss device and method |
US4607618A (en) * | 1983-02-23 | 1986-08-26 | Angelchik Jean P | Method for treatment of morbid obesity |
US4795463A (en) * | 1984-10-03 | 1989-01-03 | Baylor College Of Medicine | Labeled breast prosthesis and methods for detecting and predicting rupture of the prosthesis |
US4648383A (en) * | 1985-01-11 | 1987-03-10 | Angelchik Jean P | Peroral apparatus for morbid obesity treatment |
US4723893A (en) * | 1985-07-10 | 1988-02-09 | 501 Komatsu Zenoah Company | Portable blower |
US4694827A (en) * | 1986-01-14 | 1987-09-22 | Weiner Brian C | Inflatable gastric device for treating obesity and method of using the same |
US4739758A (en) * | 1986-05-19 | 1988-04-26 | Criticare Systems, Inc. | Apparatus for stomach cavity reduction |
US4908011A (en) * | 1986-05-22 | 1990-03-13 | Ballobes Aps | Method and device for performing a puncturing work on an inflated balloon-like object implanted in a patient |
US5084061A (en) * | 1987-09-25 | 1992-01-28 | Gau Fred C | Intragastric balloon with improved valve locating means |
US20010010024A1 (en) * | 1987-12-22 | 2001-07-26 | Ledergerber Walter J. | Tissue expander |
US5160321A (en) * | 1988-11-23 | 1992-11-03 | Harvinder Sahota | Balloon catheters |
US4983167A (en) * | 1988-11-23 | 1991-01-08 | Harvinder Sahota | Balloon catheters |
US5234454A (en) * | 1991-08-05 | 1993-08-10 | Akron City Hospital | Percutaneous intragastric balloon catheter and method for controlling body weight therewith |
US5259399A (en) * | 1992-03-02 | 1993-11-09 | Alan Brown | Device and method of causing weight loss using removable variable volume intragastric bladder |
US5476005A (en) * | 1993-07-09 | 1995-12-19 | Siemens Elema Ab | Method and apparatus for tracing leaks in vivo occurring in an electrode device of an implanted medical apparatus |
US5501667A (en) * | 1994-03-15 | 1996-03-26 | Cordis Corporation | Perfusion balloon and method of use and manufacture |
US5579765A (en) * | 1995-05-30 | 1996-12-03 | Cox; Danny L. | Monitor to detect bleeding |
US5865801A (en) * | 1995-07-18 | 1999-02-02 | Houser; Russell A. | Multiple compartmented balloon catheter with external pressure sensing |
US5833603A (en) * | 1996-03-13 | 1998-11-10 | Lipomatrix, Inc. | Implantable biosensing transponder |
US5993473A (en) * | 1997-11-19 | 1999-11-30 | Chan; Yung C. | Expandable body device for the gastric cavity and method |
US6647762B1 (en) * | 1998-03-05 | 2003-11-18 | Palmer Environmental Limited | Detecting leaks in pipes |
US6634216B1 (en) * | 1998-07-10 | 2003-10-21 | Joven Denki Kabushiki Kaisha | Inspection method for sealed package |
US6272914B1 (en) * | 1998-08-05 | 2001-08-14 | Freni Brembo, S.P.A. | Device for indicating caliper pad wear in disc brakes |
US6736793B2 (en) * | 1999-02-02 | 2004-05-18 | Ams Research Corporation | Self-sealing detachable balloon |
US6427089B1 (en) * | 1999-02-19 | 2002-07-30 | Edward W. Knowlton | Stomach treatment apparatus and method |
US6454785B2 (en) * | 2000-02-24 | 2002-09-24 | DE HOYOS GARZA ANDRéS | Percutaneous intragastric balloon catheter for the treatment of obesity |
US20050107664A1 (en) * | 2000-03-24 | 2005-05-19 | Kalloo Anthony N. | Methods and devices for diagnostic and therapeutic interventions in the peritoneal cavity |
US20020055757A1 (en) * | 2000-11-03 | 2002-05-09 | Torre Roger De La | Method and device for use in minimally invasive placement of intragastric devices |
US7033373B2 (en) * | 2000-11-03 | 2006-04-25 | Satiety, Inc. | Method and device for use in minimally invasive placement of space-occupying intragastric devices |
US6579301B1 (en) * | 2000-11-17 | 2003-06-17 | Syntheon, Llc | Intragastric balloon device adapted to be repeatedly varied in volume without external assistance |
US20040059289A1 (en) * | 2001-03-09 | 2004-03-25 | Jose Rafael Garza Alvarez | Intragastric balloon assembly |
US7066945B2 (en) * | 2001-05-17 | 2006-06-27 | Wilson-Cook Medical Inc. | Intragastric device for treating obesity |
US20030171768A1 (en) * | 2002-03-07 | 2003-09-11 | Mcghan Jim J. | Self-deflating intragastric balloon |
US6733512B2 (en) * | 2002-03-07 | 2004-05-11 | Mcghan Jim J. | Self-deflating intragastric balloon |
US6746460B2 (en) * | 2002-08-07 | 2004-06-08 | Satiety, Inc. | Intra-gastric fastening devices |
US20040044357A1 (en) * | 2002-08-30 | 2004-03-04 | James Gannoe | Stented anchoring of gastric space-occupying devices |
US6656194B1 (en) * | 2002-11-05 | 2003-12-02 | Satiety, Inc. | Magnetic anchoring devices |
US20040102712A1 (en) * | 2002-11-25 | 2004-05-27 | Andres Belalcazar | Impedance monitoring for detecting pulmonary edema and thoracic congestion |
US20040106899A1 (en) * | 2002-11-30 | 2004-06-03 | Mcmichael Donald J. | Gastric balloon catheter with improved balloon orientation |
US20040122526A1 (en) * | 2002-12-23 | 2004-06-24 | Imran Mir A. | Stomach prosthesis |
US20050149186A1 (en) * | 2003-02-06 | 2005-07-07 | Rfs Health Sciences, Inc. | Cosmetic and reconstructive prosthesis containing a biologically compatible rupture indicator |
US20040186503A1 (en) * | 2003-03-17 | 2004-09-23 | Delegge Rebecca | Intragastric catheter |
US20040186502A1 (en) * | 2003-03-19 | 2004-09-23 | Sampson Douglas C. | Self-Inflating intragastric volume-occupying device |
US20050055039A1 (en) * | 2003-07-28 | 2005-03-10 | Polymorfix, Inc. | Devices and methods for pyloric anchoring |
US20050033331A1 (en) * | 2003-07-28 | 2005-02-10 | Polymorfix, Inc., C/O Medventure Associates | Pyloric valve obstructing devices and methods |
US20050181977A1 (en) * | 2003-11-10 | 2005-08-18 | Angiotech International Ag | Medical implants and anti-scarring agents |
US20060004272A1 (en) * | 2003-11-13 | 2006-01-05 | Rajiv Shah | Long term analyte sensor array |
US20050192614A1 (en) * | 2004-02-26 | 2005-09-01 | Binmoeller Kenneth F. | Method and apparatus for reducing obesity |
US20060178691A1 (en) * | 2004-02-26 | 2006-08-10 | Binmoeller Kenneth F | Methods and devices to curb appetite and/or reduce food intake |
US20050273060A1 (en) * | 2004-06-03 | 2005-12-08 | Mayo Foundation For Medical Education And Research | Obesity treatment and device |
Cited By (274)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8096938B2 (en) | 1999-08-12 | 2012-01-17 | Obtech Medical Ag | Controlled anal incontinence disease treatment |
US8545384B2 (en) | 1999-08-12 | 2013-10-01 | Obtech Medical Ag | Anal incontinence disease treatment with controlled wireless energy supply |
US8287444B2 (en) | 2000-02-10 | 2012-10-16 | Obtech Medical Ag | Mechanical impotence treatment apparatus |
US8096939B2 (en) | 2000-02-10 | 2012-01-17 | Obtech Medical Ag | Urinary incontinence treatment with wireless energy supply |
US8602966B2 (en) | 2000-02-10 | 2013-12-10 | Obtech Medical, AG | Mechanical impotence treatment apparatus |
US8556796B2 (en) | 2000-02-10 | 2013-10-15 | Obtech Medical Ag | Controlled urinary incontinence treatment |
US20100145138A1 (en) * | 2000-02-10 | 2010-06-10 | Obtech Medical Ag | Urinary incontinence treatment with wireless energy supply |
US8290594B2 (en) | 2000-02-11 | 2012-10-16 | Obtech Medical Ag | Impotence treatment apparatus with energy transforming means |
US8734318B2 (en) | 2000-02-11 | 2014-05-27 | Obtech Medical Ag | Mechanical anal incontinence |
US8764627B2 (en) | 2000-02-14 | 2014-07-01 | Obtech Medical Ag | Penile prosthesis |
US8313423B2 (en) | 2000-02-14 | 2012-11-20 | Peter Forsell | Hydraulic anal incontinence treatment |
US8126558B2 (en) | 2000-02-14 | 2012-02-28 | Obtech Medical Ag | Controlled penile prosthesis |
US8678997B2 (en) | 2000-02-14 | 2014-03-25 | Obtech Medical Ag | Male impotence prosthesis apparatus with wireless energy supply |
US8784354B2 (en) | 2001-08-27 | 2014-07-22 | Boston Scientific Scimed, Inc. | Positioning tools and methods for implanting medical devices |
US9138340B2 (en) | 2001-08-27 | 2015-09-22 | Boston Scientific Scimed, Inc. | Gastro-esophageal implants |
US8992457B2 (en) | 2001-08-27 | 2015-03-31 | Boston Scientific Scimed, Inc. | Gastrointestinal implants |
US9788984B2 (en) | 2001-08-27 | 2017-10-17 | Boston Scientific Scimed, Inc. | Satiation devices and methods |
US9254214B2 (en) | 2001-08-27 | 2016-02-09 | Boston Scientific Scimed, Inc. | Satiation devices and methods |
US7892292B2 (en) | 2001-08-27 | 2011-02-22 | Synecor, Llc | Positioning tools and methods for implanting medical devices |
US10080677B2 (en) | 2001-08-27 | 2018-09-25 | Boston Scientific Scimed, Inc. | Satiation devices and methods |
US8568488B2 (en) | 2001-08-27 | 2013-10-29 | Boston Scientific Scimed, Inc. | Satiation devices and methods |
US9872786B2 (en) | 2001-08-27 | 2018-01-23 | Boston Scientific Scimed, Inc. | Gastro-esophageal implants |
US9107727B2 (en) | 2001-08-27 | 2015-08-18 | Boston Scientific Scimed, Inc. | Satiation devices and methods |
US9180036B2 (en) | 2001-08-27 | 2015-11-10 | Boston Scientific Scimed, Inc. | Methods for implanting medical devices |
US8845753B2 (en) | 2001-08-27 | 2014-09-30 | Boston Scientific Scimed, Inc. | Satiation devices and methods |
US9358144B2 (en) | 2001-08-27 | 2016-06-07 | Boston Scientific Scimed, Inc. | Gastrointestinal implants |
US9844453B2 (en) | 2001-08-27 | 2017-12-19 | Boston Scientific Scimed, Inc. | Positioning tools and methods for implanting medical devices |
US8337566B2 (en) | 2002-04-08 | 2012-12-25 | Barosense, Inc. | Method and apparatus for modifying the exit orifice of a satiation pouch |
US9668900B2 (en) | 2002-05-09 | 2017-06-06 | Reshape Medical, Inc. | Balloon system and methods for treating obesity |
US8845672B2 (en) | 2002-05-09 | 2014-09-30 | Reshape Medical, Inc. | Balloon system and methods for treating obesity |
US8029455B2 (en) | 2003-01-16 | 2011-10-04 | Barosense, Inc. | Satiation pouches and methods of use |
US7749254B2 (en) | 2003-06-20 | 2010-07-06 | Allergan, Inc. | Two-way slit valve |
US20060142700A1 (en) * | 2003-06-20 | 2006-06-29 | Sobelman Owen S | Two-way slit valve |
US10010440B2 (en) | 2003-06-20 | 2018-07-03 | Apollo Endosurgery Us, Inc. | Intragastric balloon system |
US9174033B2 (en) | 2003-06-20 | 2015-11-03 | Apollo Endosurgery, Inc. | Two-way slit valve |
US10016294B2 (en) | 2003-06-20 | 2018-07-10 | Apollo Endosurgery Us, Inc. | Method of implanting an intragastric balloon |
US20100274194A1 (en) * | 2003-06-20 | 2010-10-28 | Allergan, Inc. | Two-way slit valve |
US8192455B2 (en) | 2003-08-13 | 2012-06-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compressive device for percutaneous treatment of obesity |
US9445791B2 (en) | 2003-10-10 | 2016-09-20 | Boston Scientific Scimed, Inc. | Systems and methods related to gastro-esophageal implants |
US10285836B2 (en) | 2003-10-10 | 2019-05-14 | Boston Scientific Scimed, Inc. | Systems and methods related to gastro-esophageal implants |
US8784500B2 (en) | 2003-10-10 | 2014-07-22 | Boston Scientific Scimed, Inc. | Devices and methods for retaining a gastro-esophageal implant |
US9248038B2 (en) | 2003-10-10 | 2016-02-02 | Boston Scientific Scimed, Inc. | Methods for retaining a gastro-esophageal implant |
US9180035B2 (en) | 2003-10-10 | 2015-11-10 | Boston Scientific Scimed, Inc. | Devices and methods for retaining a gastro-esophageal implant |
US8206456B2 (en) | 2003-10-10 | 2012-06-26 | Barosense, Inc. | Restrictive and/or obstructive implant system for inducing weight loss |
US10098773B2 (en) | 2004-04-26 | 2018-10-16 | Boston Scientific Scimed, Inc. | Restrictive and/or obstructive implant for inducing weight loss |
US20100204719A1 (en) * | 2004-04-26 | 2010-08-12 | Balbierz Daniel J | Restrictive and/or obstructive implant for inducing weight loss |
US7717843B2 (en) | 2004-04-26 | 2010-05-18 | Barosense, Inc. | Restrictive and/or obstructive implant for inducing weight loss |
US20050261712A1 (en) * | 2004-04-26 | 2005-11-24 | Balbierz Daniel J | Restrictive and/or obstructive implant for inducing weight loss |
US8241202B2 (en) | 2004-04-26 | 2012-08-14 | Barosense, Inc. | Restrictive and/or obstructive implant for inducing weight loss |
US20090275973A1 (en) * | 2004-05-03 | 2009-11-05 | Fulfillium, Inc. | Devices and systems for gastric volume control |
US10285835B2 (en) | 2004-11-19 | 2019-05-14 | Fulfillium, Inc. | Methods, devices, and systems for obesity treatment |
US9456915B2 (en) | 2004-11-19 | 2016-10-04 | Fulfilium, Inc. | Methods, devices, and systems for obesity treatment |
US9808367B2 (en) | 2004-11-19 | 2017-11-07 | Fulfillium, Inc. | Methods, devices, and systems for obesity treatment |
US10179060B2 (en) | 2004-11-19 | 2019-01-15 | Fulfillium, Inc. | Methods, devices, and systems for obesity treatment |
US9445930B2 (en) | 2004-11-19 | 2016-09-20 | Fulfillium, Inc. | Methods, devices, and systems for obesity treatment |
US11026825B2 (en) | 2004-11-19 | 2021-06-08 | Fulfillium, Inc. | Methods, devices, and systems for obesity treatment |
US10524946B2 (en) | 2004-11-19 | 2020-01-07 | Fulfillium, Inc. | Methods, devices, and systems for obesity treatment |
US20060142731A1 (en) * | 2004-12-27 | 2006-06-29 | Jeffrey Brooks | Floating gastro-intestinal anchor |
US9974680B2 (en) | 2004-12-27 | 2018-05-22 | Spatz Fgia, Inc. | System and methods for internalization of external components of adjustable intragastric balloon |
US20100016871A1 (en) * | 2004-12-27 | 2010-01-21 | Spatz-Fgia, Inc. | Floating gastrointestinal anchor |
US8403952B2 (en) | 2004-12-27 | 2013-03-26 | Spatz-Fgia, Inc. | Floating gastrointestinal anchor |
US8469977B2 (en) | 2005-10-03 | 2013-06-25 | Barosense, Inc. | Endoscopic plication device and method |
US9055942B2 (en) | 2005-10-03 | 2015-06-16 | Boston Scienctific Scimed, Inc. | Endoscopic plication devices and methods |
US10299796B2 (en) | 2005-10-03 | 2019-05-28 | Boston Scientific Scimed, Inc. | Endoscopic plication devices and methods |
US9962276B2 (en) * | 2005-10-31 | 2018-05-08 | Reshape Medical Llc | Intragastric space filler |
US20070100367A1 (en) * | 2005-10-31 | 2007-05-03 | Quijano Rodolfo C | Intragastric space filler |
US20070100368A1 (en) * | 2005-10-31 | 2007-05-03 | Quijano Rodolfo C | Intragastric space filler |
US20070100369A1 (en) * | 2005-10-31 | 2007-05-03 | Cragg Andrew H | Intragastric space filler |
US11311702B2 (en) | 2005-12-16 | 2022-04-26 | Confluent Medical Technologies, Inc. | Methods for manufacturing multi-layer balloons for medical applications |
US8568648B2 (en) | 2005-12-16 | 2013-10-29 | Interface Associates, Inc. | Methods for manufacturing multi-layer balloons for medical applications |
US10835720B2 (en) | 2005-12-16 | 2020-11-17 | Confluent Medical Technologies, Inc. | Methods for manufacturing multi-layer balloons for medical applications |
US9833600B2 (en) | 2005-12-16 | 2017-12-05 | Interface Associates, Inc. | Methods for manufacturing multi-layer balloons for medical applications |
WO2007075978A3 (en) * | 2005-12-22 | 2007-11-29 | Wilson Cook Medical Inc | Coiled intragastric member for treating obesity |
WO2007075810A1 (en) * | 2005-12-22 | 2007-07-05 | Abdominus, Inc. | Intragastric space filler |
US20070149994A1 (en) * | 2005-12-22 | 2007-06-28 | Sosnowski Stephen A | Intragastric space filler and methods of manufacture |
JP2009521275A (en) * | 2005-12-22 | 2009-06-04 | リシェイプ メディカル, インコーポレイテッド | Stomach filling device |
AU2006331503B2 (en) * | 2005-12-22 | 2012-09-06 | Cook Medical Technologies Llc | Coiled intragastric member for treating obesity |
US20110218563A1 (en) * | 2006-03-28 | 2011-09-08 | Spatz-Fgia, Inc. | Floating gastrointestinal anchor |
EP2356956A1 (en) | 2006-03-28 | 2011-08-17 | Spatz-Fgia Inc. | Floating gastrointestinal anchor |
US8430894B2 (en) | 2006-03-28 | 2013-04-30 | Spatz-Fgia, Inc. | Floating gastrointestinal anchor |
US8430895B2 (en) | 2006-03-28 | 2013-04-30 | Spatz-Fgia, Inc. | Floating gastrointestinal anchor |
US7976554B2 (en) | 2006-04-19 | 2011-07-12 | Vibrynt, Inc. | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US8356605B2 (en) | 2006-04-19 | 2013-01-22 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8585733B2 (en) | 2006-04-19 | 2013-11-19 | Vibrynt, Inc | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US8187297B2 (en) | 2006-04-19 | 2012-05-29 | Vibsynt, Inc. | Devices and methods for treatment of obesity |
US8460321B2 (en) | 2006-04-19 | 2013-06-11 | Vibrynt, Inc. | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US8398668B2 (en) | 2006-04-19 | 2013-03-19 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8070768B2 (en) | 2006-04-19 | 2011-12-06 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8001974B2 (en) | 2006-04-19 | 2011-08-23 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8360069B2 (en) | 2006-04-19 | 2013-01-29 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8342183B2 (en) | 2006-04-19 | 2013-01-01 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8353925B2 (en) | 2006-04-19 | 2013-01-15 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20100168783A1 (en) * | 2006-06-09 | 2010-07-01 | Allergan, Inc. | Intragastric balloon retrieval mechanisms |
US8753369B2 (en) | 2006-06-09 | 2014-06-17 | Apollo Endosurgery, Inc. | Intragastric balloon retrieval mechanisms |
US20070288033A1 (en) * | 2006-06-09 | 2007-12-13 | Allergan, Inc. | Intragastric balloon retrieval mechanisms |
US9125726B2 (en) | 2006-06-09 | 2015-09-08 | Apollo Endosurgery, Inc. | Intragastric balloon retrieval mechanisms |
EP2401991A3 (en) * | 2006-07-24 | 2012-03-21 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20080109027A1 (en) * | 2006-08-01 | 2008-05-08 | Fulfillium, Inc. | Method and system for gastric volume control |
US20080097510A1 (en) * | 2006-09-01 | 2008-04-24 | Albrecht Thomas E | Method for inducing weight loss with a patient |
US8109895B2 (en) | 2006-09-02 | 2012-02-07 | Barosense, Inc. | Intestinal sleeves and associated deployment systems and methods |
US9687334B2 (en) | 2006-09-02 | 2017-06-27 | Boston Scientific Scimed, Inc. | Intestinal sleeves and associated deployment systems and methods |
US9314361B2 (en) | 2006-09-15 | 2016-04-19 | Boston Scientific Scimed, Inc. | System and method for anchoring stomach implant |
US20080172079A1 (en) * | 2006-09-29 | 2008-07-17 | Allergan, Inc. | Apparatus and method for intragastric balloon with in situ adjustment means |
US9326877B2 (en) | 2006-09-29 | 2016-05-03 | Apollo Endosurgery, Inc. | Apparatus and method for intragastric balloon with in situ adjustment means |
US20080086082A1 (en) * | 2006-10-06 | 2008-04-10 | Brooks Jeffrey S | Radiopaque marking to detect balloon deflation |
WO2008085290A2 (en) * | 2006-12-28 | 2008-07-17 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
WO2008085290A3 (en) * | 2006-12-28 | 2008-10-02 | Vibrynt Inc | Devices and methods for treatment of obesity |
WO2008085291A3 (en) * | 2006-12-28 | 2008-10-23 | Vibrynt Inc | Devices and methods for treatment of obesity |
US8926648B2 (en) * | 2007-02-13 | 2015-01-06 | Brian Charles Weiner | Multi-method and multi-apparatus for treating obesity |
US20080208241A1 (en) * | 2007-02-13 | 2008-08-28 | Brian Charles Weiner | Multi-method and multi-apparatus for treating obesity |
US8821429B2 (en) * | 2007-03-29 | 2014-09-02 | IBIS Medical, Inc. | Intragastric implant devices |
US20100049224A1 (en) * | 2007-03-29 | 2010-02-25 | Jaime Vargas | Intragastric Implant Devices |
US8226602B2 (en) | 2007-03-30 | 2012-07-24 | Reshape Medical, Inc. | Intragastric balloon system and therapeutic processes and products |
US9173757B2 (en) | 2007-04-13 | 2015-11-03 | Apollo Endosurgery, Inc. | Apparatus and method for remote deflation of intragastric balloon |
US20080255601A1 (en) * | 2007-04-13 | 2008-10-16 | Allergan, Inc. | Apparatus and method for remote deflation of intragastric balloon |
US20100174307A1 (en) * | 2007-04-13 | 2010-07-08 | Allergan, Inc. | Remote deflation of intragastric balloon |
US20100121371A1 (en) * | 2007-04-30 | 2010-05-13 | Spatz Fgia, Inc. | Non-endoscopic insertion and removal of a device |
US9283102B2 (en) | 2007-06-25 | 2016-03-15 | Reshape Medical, Inc. | Gastric space filler device, delivery system, and related methods |
US8142469B2 (en) | 2007-06-25 | 2012-03-27 | Reshape Medical, Inc. | Gastric space filler device, delivery system, and related methods |
US9456825B2 (en) | 2007-07-18 | 2016-10-04 | Boston Scientific Scimed, Inc. | Endoscopic implant system and method |
US10537456B2 (en) | 2007-07-18 | 2020-01-21 | Boston Scientific Scimed, Inc. | Endoscopic implant system and method |
US9545249B2 (en) | 2007-07-18 | 2017-01-17 | Boston Scientific Scimed, Inc. | Overtube introducer for use in endoscopic bariatric surgery |
WO2009048496A1 (en) * | 2007-10-11 | 2009-04-16 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8556925B2 (en) * | 2007-10-11 | 2013-10-15 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20090131968A1 (en) * | 2007-10-23 | 2009-05-21 | Allergan, Inc. | Pressure sensing intragastric balloon |
US8282666B2 (en) | 2007-10-23 | 2012-10-09 | Allergan, Inc. | Pressure sensing intragastric balloon |
US8016851B2 (en) * | 2007-12-27 | 2011-09-13 | Cook Medical Technologies Llc | Delivery system and method of delivery for treating obesity |
US8945167B2 (en) | 2007-12-31 | 2015-02-03 | Boston Scientific Scimed, Inc. | Gastric space occupier systems and methods of use |
US9694165B2 (en) * | 2008-01-28 | 2017-07-04 | Peter Mats Forsell | Implantable drainage device |
US20150157836A1 (en) * | 2008-01-28 | 2015-06-11 | Peter Mats Forsell | Implantable drainage device |
US8961448B2 (en) | 2008-01-28 | 2015-02-24 | Peter Forsell | Implantable drainage device |
US20100331614A1 (en) * | 2008-01-29 | 2010-12-30 | Peter Forsell | Methods and instruments for treating obesity and gastroesophageal reflux disease |
US20100331615A1 (en) * | 2008-01-29 | 2010-12-30 | Peter Forsell | Method and instruments for treating gerd |
US9687335B2 (en) | 2008-01-29 | 2017-06-27 | Milux Holding Sa | Method and instruments for treating GERD |
US10045869B2 (en) | 2008-01-29 | 2018-08-14 | Peter Forsell | Apparatus for treating obesity and reflux disease |
US8636809B2 (en) | 2008-01-29 | 2014-01-28 | Milux Holding Sa | Device for treating obesity |
US8567409B2 (en) | 2008-01-29 | 2013-10-29 | Milux Holding Sa | Method and instruments for treating GERD |
US20100324362A1 (en) * | 2008-01-29 | 2010-12-23 | Peter Forsell | Apparatus for treating obesity and reflux disease |
US20100324361A1 (en) * | 2008-01-29 | 2010-12-23 | Peter Forsell | Apparatus for treating obesity |
US10945870B2 (en) | 2008-01-29 | 2021-03-16 | Peter Forsell | Apparatus for treating obesity |
US8992629B2 (en) | 2008-01-29 | 2015-03-31 | Peter Forsell | Methods and instruments for treating GERD and hiatal hernia |
US20100312049A1 (en) * | 2008-01-29 | 2010-12-09 | Peter Forsell | Apparatus for treating obesity |
US10857018B2 (en) | 2008-01-29 | 2020-12-08 | Peter Forsell | Apparatus for treating obesity |
US9060771B2 (en) | 2008-01-29 | 2015-06-23 | Peter Forsell | Method and instrument for treating obesity |
US10653543B2 (en) | 2008-01-29 | 2020-05-19 | Peter Forsell | Apparatus for treating GERD |
US9877859B2 (en) | 2008-01-29 | 2018-01-30 | Peter Forsell | Methods and instruments for treating obesity and gastroesophageal reflux disease |
US7909219B2 (en) | 2008-03-18 | 2011-03-22 | Barosense, Inc. | Endoscopic stapling devices and methods |
US8020741B2 (en) | 2008-03-18 | 2011-09-20 | Barosense, Inc. | Endoscopic stapling devices and methods |
US7909223B2 (en) | 2008-03-18 | 2011-03-22 | Barosense, Inc. | Endoscopic stapling devices and methods |
US7909222B2 (en) | 2008-03-18 | 2011-03-22 | Barosense, Inc. | Endoscopic stapling devices and methods |
US7913892B2 (en) | 2008-03-18 | 2011-03-29 | Barosense, Inc. | Endoscopic stapling devices and methods |
US7922062B2 (en) | 2008-03-18 | 2011-04-12 | Barosense, Inc. | Endoscopic stapling devices and methods |
US8864008B2 (en) | 2008-03-18 | 2014-10-21 | Boston Scientific Scimed, Inc. | Endoscopic stapling devices and methods |
US9636114B2 (en) | 2008-03-18 | 2017-05-02 | Boston Scientific Scimed, Inc. | Endoscopic stapling devices |
US20090298180A1 (en) * | 2008-05-30 | 2009-12-03 | Cattadoris Henry J | Cell culture apparatus and method |
US8058057B2 (en) | 2008-05-30 | 2011-11-15 | Corning Incorporated | Cell culture apparatus and method |
WO2010042062A1 (en) * | 2008-10-10 | 2010-04-15 | Milux Holding S.A. | An apparatus for treating gerd |
US11090179B2 (en) | 2008-10-10 | 2021-08-17 | Peter Forsell | Apparatus for treating GERD |
US20110196391A1 (en) * | 2008-10-10 | 2011-08-11 | Milux Holding Sa | Apparatus for treating gerd |
US8600510B2 (en) | 2008-10-10 | 2013-12-03 | Milux Holding Sa | Apparatus, system and operation method for the treatment of female sexual dysfunction |
US20110218394A1 (en) * | 2008-10-10 | 2011-09-08 | Milux Holding Sa | Apparatus and method for treating gerd |
US8696745B2 (en) | 2008-10-10 | 2014-04-15 | Kirk Promotion Ltd. | Heart help device, system, and method |
US8509894B2 (en) | 2008-10-10 | 2013-08-13 | Milux Holding Sa | Heart help device, system, and method |
US8874215B2 (en) | 2008-10-10 | 2014-10-28 | Peter Forsell | System, an apparatus, and a method for treating a sexual dysfunctional female patient |
WO2010042061A1 (en) * | 2008-10-10 | 2010-04-15 | Milux Holding S.A. | Apparatus and method for treating gerd |
US9072907B2 (en) | 2008-10-10 | 2015-07-07 | Peter Forsell | Heart help device, system, and method |
US10583234B2 (en) | 2008-10-10 | 2020-03-10 | Peter Forsell | Heart help device, system and method |
US11707373B2 (en) | 2008-10-10 | 2023-07-25 | Peter Forsell | Apparatus and method for treating GERD |
US9526649B2 (en) | 2008-10-10 | 2016-12-27 | Peter Forsell | Method and instrument for treating obesity |
US20110196197A1 (en) * | 2008-10-10 | 2011-08-11 | Milux Holdings SA | Apparatus for treating obesity |
WO2010042063A1 (en) * | 2008-10-10 | 2010-04-15 | Milux Holding S.A. | Apparatus for treating obesity |
US10219898B2 (en) | 2008-10-10 | 2019-03-05 | Peter Forsell | Artificial valve |
US11123171B2 (en) | 2008-10-10 | 2021-09-21 | Peter Forsell | Fastening means for implantable medical control assembly |
US9375213B2 (en) | 2008-10-10 | 2016-06-28 | Peter Forsell | Methods and instruments for treating obesity |
AU2009302908B2 (en) * | 2008-10-10 | 2016-05-05 | Implantica Patent Ltd. | Apparatus for treating obesity |
US9370656B2 (en) | 2008-10-10 | 2016-06-21 | Peter Forsell | System, an apparatus, and a method for treating a sexual dysfunctional female patient |
US11559383B2 (en) | 2008-10-10 | 2023-01-24 | Peter Forsell | Apparatus for treating GERD |
US9561033B2 (en) | 2008-10-10 | 2017-02-07 | Peter Forsell | Apparatus for treating obesity |
US7934631B2 (en) | 2008-11-10 | 2011-05-03 | Barosense, Inc. | Multi-fire stapling systems and methods for delivering arrays of staples |
US11202627B2 (en) | 2008-11-10 | 2021-12-21 | Boston Scientific Scimed, Inc. | Multi-fire stapling systems and methods for delivering arrays of staples |
US8747421B2 (en) | 2008-11-10 | 2014-06-10 | Boston Scientific Scimed, Inc. | Multi-fire stapling systems and methods for delivering arrays of staples |
US9451956B2 (en) | 2008-11-10 | 2016-09-27 | Boston Scientific Scimed, Inc. | Multi-fire stapling systems |
US10368862B2 (en) | 2008-11-10 | 2019-08-06 | Boston Scientific Scimed, Inc. | Multi-fire stapling methods |
WO2010066761A1 (en) * | 2008-12-09 | 2010-06-17 | Compagnie Europeenne D'etude Et De Recherche De Dispositifs Pour L'implantation Par Laparoscopie | Implantable device with a multi-layer envelope, and corresponding method of production |
US8758385B2 (en) * | 2008-12-27 | 2014-06-24 | John Hancock | High specific gravity intragastric device |
US20100168782A1 (en) * | 2008-12-27 | 2010-07-01 | John Hancock | High specific gravity intragastric device |
WO2010087757A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | Obesity treatment |
US10226372B2 (en) | 2009-01-29 | 2019-03-12 | Peter Forsell | Obesity treatment |
WO2010087773A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | An apparatus for treating gerd |
WO2010087774A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | Obesity treatment |
WO2010087772A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A. | An apparatus for treating gerd |
CN102365065A (en) * | 2009-01-29 | 2012-02-29 | 米卢克斯控股股份有限公司 | Obesity treatment |
US10925764B2 (en) | 2009-01-29 | 2021-02-23 | Peter Forsell | Obesity treatment |
US9174031B2 (en) | 2009-03-13 | 2015-11-03 | Reshape Medical, Inc. | Device and method for deflation and removal of implantable and inflatable devices |
US20120123465A1 (en) * | 2009-03-31 | 2012-05-17 | Raj Nihalani | Method and apparatus for treating obesity and controlling weight gain using self-expanding intragastric devices |
US9055994B2 (en) * | 2009-03-31 | 2015-06-16 | Onciomed, Inc. | Method and apparatus for treating obesity and controlling weight gain using self-expanding intragastric devices |
USRE47902E1 (en) * | 2009-03-31 | 2020-03-17 | Reshape Lifesciences, Inc. | Method and apparatus for treating obesity and controlling weight gain using self-expanding intragastric devices |
US8840952B2 (en) | 2009-04-03 | 2014-09-23 | Reshape Medical, Inc. | Intragastric space fillers and methods of manufacturing including in vitro testing |
US8683881B2 (en) | 2009-04-03 | 2014-04-01 | Reshape Medical, Inc. | Intragastric space fillers and methods of manufacturing including in vitro testing |
US8961539B2 (en) | 2009-05-04 | 2015-02-24 | Boston Scientific Scimed, Inc. | Endoscopic implant system and method |
US9949812B2 (en) | 2009-07-17 | 2018-04-24 | Peter Forsell | Vaginal operation method for the treatment of anal incontinence in women |
US10952836B2 (en) | 2009-07-17 | 2021-03-23 | Peter Forsell | Vaginal operation method for the treatment of urinary incontinence in women |
US9358143B2 (en) | 2009-07-22 | 2016-06-07 | Reshape Medical, Inc. | Retrieval mechanisms for implantable medical devices |
US9604038B2 (en) | 2009-07-23 | 2017-03-28 | Reshape Medical, Inc. | Inflation and deflation mechanisms for inflatable medical devices |
US9987470B2 (en) | 2009-07-23 | 2018-06-05 | ReShape Medical, LLC | Deflation and removal of implantable medical devices |
US9050174B2 (en) | 2009-07-23 | 2015-06-09 | Reshape Medical, Inc. | Deflation and removal of implantable medical devices |
US8894568B2 (en) | 2009-09-24 | 2014-11-25 | Reshape Medical, Inc. | Normalization and stabilization of balloon surfaces for deflation |
US9173734B2 (en) | 2009-09-29 | 2015-11-03 | IBIS Medical, Inc. | Intragastric implant devices |
US20110092998A1 (en) * | 2009-10-13 | 2011-04-21 | Spatz Fgia, Inc. | Balloon hydraulic and gaseous expansion system |
US9072579B2 (en) | 2009-10-21 | 2015-07-07 | Apollo Endosurgery, Inc. | Bariatric device and method for weight loss |
US9532892B2 (en) | 2009-10-21 | 2017-01-03 | Apollo Endosurgery, Inc. | Bariatric device and method for weight loss |
US10111771B2 (en) | 2009-10-21 | 2018-10-30 | Apollo Endosurgery Us, Inc. | Bariatric device and method for weight loss |
US9622896B2 (en) | 2010-02-08 | 2017-04-18 | Reshape Medical, Inc. | Enhanced aspiration processes and mechanisms for instragastric devices |
US9149611B2 (en) | 2010-02-08 | 2015-10-06 | Reshape Medical, Inc. | Materials and methods for improved intragastric balloon devices |
US9579226B2 (en) | 2010-02-08 | 2017-02-28 | Reshape Medical, Inc. | Materials and methods for improved intragastric balloon devices |
US9681973B2 (en) | 2010-02-25 | 2017-06-20 | Reshape Medical, Inc. | Enhanced explant processes and mechanisms for intragastric devices |
US9155650B2 (en) | 2010-03-15 | 2015-10-13 | Apollo Endosurgery, Inc. | Bariatric device and method for weight loss |
US9629740B2 (en) | 2010-04-06 | 2017-04-25 | Reshape Medical, Inc. | Inflation devices for intragastric devices with improved attachment and detachment and associated systems and methods |
US10117766B2 (en) | 2010-04-06 | 2018-11-06 | Reshape Medical Llc | Inflation devices for intragastric devices with improved attachment and detachment and associated systems and methods |
US9192501B2 (en) | 2010-04-30 | 2015-11-24 | Apollo Endosurgery, Inc. | Remotely powered remotely adjustable gastric band system |
US11950778B2 (en) | 2010-05-21 | 2024-04-09 | Boston Scientific Scimed, Inc. | Tissue-acquisition and fastening devices and methods |
US10617538B2 (en) | 2010-06-08 | 2020-04-14 | Regents Of The University Of Minnesota | Vascular elastance |
US9987153B2 (en) | 2010-06-08 | 2018-06-05 | The Regents Of The University Of Minnesota | Vascular elastance |
US11583420B2 (en) | 2010-06-08 | 2023-02-21 | Regents Of The University Of Minnesota | Vascular elastance |
WO2011156176A1 (en) * | 2010-06-08 | 2011-12-15 | Regents Of The University Of Minnesota | Vascular elastance |
US9795498B2 (en) | 2010-10-18 | 2017-10-24 | Apollo Endosurgery Us, Inc. | Intragastric balloon for treating obesity |
US9233016B2 (en) | 2010-10-18 | 2016-01-12 | Apollo Endosurgery, Inc. | Elevating stomach stimulation device |
US8870966B2 (en) | 2010-10-18 | 2014-10-28 | Apollo Endosurgery, Inc. | Intragastric balloon for treating obesity |
US9463107B2 (en) | 2010-10-18 | 2016-10-11 | Apollo Endosurgery, Inc. | Variable size intragastric implant devices |
US8956380B2 (en) | 2010-10-18 | 2015-02-17 | Apollo Endosurgery, Inc. | Reactive intragastric implant devices |
US9668901B2 (en) | 2010-10-18 | 2017-06-06 | Apollo Endosurgery Us, Inc. | Intragastric implants with duodenal anchors |
US9539133B2 (en) | 2010-10-19 | 2017-01-10 | Apollo Endosurgery, Inc. | Stomach-spanning gastric implants |
US9681974B2 (en) | 2010-10-19 | 2017-06-20 | Apollo Endosurgery Us, Inc. | Intragastric implants with collapsible frames |
US9498365B2 (en) | 2010-10-19 | 2016-11-22 | Apollo Endosurgery, Inc. | Intragastric implants with multiple fluid chambers |
US9198790B2 (en) | 2010-10-19 | 2015-12-01 | Apollo Endosurgery, Inc. | Upper stomach gastric implants |
US8864840B2 (en) | 2010-10-19 | 2014-10-21 | Apollo Endosurgery, Inc. | Intragastric implants with collapsible frames |
WO2012054410A3 (en) * | 2010-10-19 | 2012-08-02 | Allergan, Inc. | Intragastric implants with multiple fluid chambers |
US9398969B2 (en) | 2010-10-19 | 2016-07-26 | Apollo Endosurgery, Inc. | Upper stomach gastric implants |
WO2012054411A3 (en) * | 2010-10-19 | 2012-06-28 | Allergan, Inc. | Upper stomach gastric implants |
US9095405B2 (en) | 2010-10-19 | 2015-08-04 | Apollo Endosurgery, Inc. | Space-filling intragastric implants with fluid flow |
US9801747B2 (en) | 2010-10-19 | 2017-10-31 | Apollo Endosurgery Us, Inc. | Non-inflatable gastric implants and systems |
US10070980B2 (en) | 2010-10-19 | 2018-09-11 | Apollo Endosurgery Us, Inc. | Anchored non-piercing duodenal sleeve and delivery systems |
US8920447B2 (en) | 2010-10-19 | 2014-12-30 | Apollo Endosurgery, Inc. | Articulated gastric implant clip |
US9895247B2 (en) | 2010-10-19 | 2018-02-20 | Apollo Endosurgery Us, Inc. | Space-filling intragastric implants with fluid flow |
US10702682B2 (en) | 2010-11-22 | 2020-07-07 | Aria Cv, Inc. | System and method for reducing pulsatile pressure |
US11406803B2 (en) | 2010-11-22 | 2022-08-09 | Aria Cv, Inc. | System and method for reducing pulsatile pressure |
US9333328B2 (en) | 2010-11-22 | 2016-05-10 | Aria Cv, Inc. | System and method for reducing pulsatile pressure |
US10751519B2 (en) | 2010-11-22 | 2020-08-25 | Aria Cv, Inc. | System and method for reducing pulsatile pressure |
US10350397B2 (en) | 2010-11-22 | 2019-07-16 | Aria Cv, Inc. | System and method for reducing pulsatile pressure |
US11938291B2 (en) | 2010-11-22 | 2024-03-26 | Aria Cv, Inc. | System and method for reducing pulsatile pressure |
US9017359B2 (en) | 2010-11-22 | 2015-04-28 | Aria Cv, Inc. | System and method for reducing pulsatile pressure |
US8888732B2 (en) | 2011-03-11 | 2014-11-18 | Apollo Endosurgery, Inc. | Intraluminal sleeve with active agents |
WO2013039412A1 (en) * | 2011-09-14 | 2013-03-21 | PULSMED sp. zo.o. | The method of filling an intragastric balloon |
US9155528B2 (en) | 2012-01-08 | 2015-10-13 | Vibrynt, Inc. | Methods, instruments and devices for extragastic reduction of stomach volume |
US9314362B2 (en) | 2012-01-08 | 2016-04-19 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
US8382775B1 (en) | 2012-01-08 | 2013-02-26 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
US10137023B2 (en) | 2012-09-14 | 2018-11-27 | Medibotics Llc | Colonnade (TM) expandable intragastric food flow lumen device |
US10857019B2 (en) | 2012-11-26 | 2020-12-08 | Spatz Fgia, Inc. | System and methods for internalization of external components of an adjustable intragastric balloon |
US9801989B2 (en) | 2014-06-19 | 2017-10-31 | Aria Cv, Inc. | Systems and methods for treating pulmonary hypertension |
US9039725B1 (en) | 2014-06-19 | 2015-05-26 | Aria Cv, Inc. | Systems and methods for treating pulmonary hypertension |
US9242082B2 (en) | 2014-06-19 | 2016-01-26 | Aria Cv, Inc. | Systems and methods for treating pulmonary hypertension |
US10682448B2 (en) | 2014-06-19 | 2020-06-16 | Aria Cv, Inc. | Systems and methods for treating pulmonary hypertension |
US8876850B1 (en) | 2014-06-19 | 2014-11-04 | Aria Cv, Inc. | Systems and methods for treating pulmonary hypertension |
US9610391B2 (en) | 2014-06-19 | 2017-04-04 | Aria Cv, Inc. | Systems comprising an implantable component for treating pulmonary hypertension |
US11511089B2 (en) | 2014-06-19 | 2022-11-29 | Aria Cv, Inc. | Systems and methods for treating pulmonary hypertension |
WO2016172054A1 (en) * | 2015-04-23 | 2016-10-27 | Obalon Therapeutics, Inc. | Systems and methods for preventing passage of intragastric devices |
US11331105B2 (en) | 2016-10-19 | 2022-05-17 | Aria Cv, Inc. | Diffusion resistant implantable devices for reducing pulsatile pressure |
US10893966B2 (en) | 2017-02-09 | 2021-01-19 | Spatz FGIA Ltd | Check valve with docking station for gastrointestinal balloon |
US11406801B2 (en) | 2017-10-27 | 2022-08-09 | Transit Scientific, LLC | Exoskeleton device with expandable section for scoring |
US11179549B2 (en) | 2017-10-27 | 2021-11-23 | Transit Scientific, LLC | Exoskeleton device with expandable section for scoring |
US20200069923A1 (en) * | 2018-08-29 | 2020-03-05 | Jonathan SOVEROW | Angioplasty balloon snare |
WO2021030632A1 (en) * | 2019-08-13 | 2021-02-18 | Transit Scientific, LLC | Exoskeleton device with expandable section for scoring |
US11833343B2 (en) | 2019-09-06 | 2023-12-05 | Aria Cv, Inc. | Diffusion and infusion resistant implantable devices for reducing pulsatile pressure |
US11141581B2 (en) | 2019-09-06 | 2021-10-12 | Aria Cv, Inc. | Diffusion and infusion resistant implantable devices for reducing pulsatile pressure |
Also Published As
Publication number | Publication date |
---|---|
EP1744804A2 (en) | 2007-01-24 |
WO2005107641A3 (en) | 2006-04-13 |
JP4934024B2 (en) | 2012-05-16 |
US20050267595A1 (en) | 2005-12-01 |
JP2007535999A (en) | 2007-12-13 |
WO2005107641A2 (en) | 2005-11-17 |
US20090275973A1 (en) | 2009-11-05 |
US8066780B2 (en) | 2011-11-29 |
US20160081831A1 (en) | 2016-03-24 |
US20160095730A1 (en) | 2016-04-07 |
EP1744804A4 (en) | 2009-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8066780B2 (en) | Methods for gastric volume control | |
US9445930B2 (en) | Methods, devices, and systems for obesity treatment | |
US10524946B2 (en) | Methods, devices, and systems for obesity treatment | |
US20080109027A1 (en) | Method and system for gastric volume control | |
ES2565586T3 (en) | Intragastric space filler | |
US20090082644A1 (en) | Devices, Systems, Kits and Methods for Treatment of Obesity | |
CA2680124C (en) | Intragastric balloon system and therapeutic processes and products | |
EP2817062B1 (en) | Devices for deploying and releasing a temporary implant within the body | |
CA2427603C (en) | Method and device for use in minimally invasive placement of intragastric devices | |
EP1962941B1 (en) | Intragastric space filler | |
US20170042714A1 (en) | Method and apparatus for buoyant gastric implant | |
CA2562765A1 (en) | Overweight control apparatuses for insertion into the stomach |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FULFILLIUM, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JONES, CHRISTOPHER S.;DAUSKARDT, PH.D, REINHOLD H.;TAUB, PH.D, MARC B.;REEL/FRAME:016358/0536;SIGNING DATES FROM 20050629 TO 20050722 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |